Nyeste Viden

  • 27 maj
    Original: The Journal of Pain

    Analgesic Effect of delta-9-Tetrahydrocannabinol Alone and of a 1:1 delta-9-Tetrahydrocannabinol: Cannabidiol Formulation in Chronic Neuropathic Pain: Two Pilot Studies

    These ongoing preliminary studies explore the efficacy of delta-9-tetrahydro-cannabinol (THC) alone and in a 1:1 combination with cannabidiol (CBD) in subjects with neuropathic pain (NP) in a dose-controlled process using oral formulations. Eligible subjects are 18 to 75 years of age with a diagnosis of NP existing for two or more months, not currently using […]

    Læs mere
  • 27 maj
    Original: Cannabis Cannabinoid Res .

    Anticaries and Antigingivitis Properties of Cannabinoid-Containing Oral Health Products: A Review

    To evaluate the anticaries and antigingivitis properties of cannabinoid-containing oral health products. A systematic research strategy was employed. Specific search terms were used, including “Cannabinoids AND dental caries,” “Cannabinoids AND oral health,” “Cannabinoids AND dental plaque,” “Cannabinoids AND gingivitis AND periodontitis,” “Cannabinoids AND S. mutans,” “Cannabidiol AND oral health,” and “Cannabidiol AND oral biofilm.” The […]

    Læs mere
  • 27 maj
    Original: Cannabis Cannabinoid Res .

    Impact of Dietary Fat and Oral Delivery System on Cannabigerol Pharmacokinetics in Adults

    Background and Aims: Cannabigerol (CBG) is a nonintoxicating cannabinoid synthesized in the Cannabis sativa plant that is incorporated into dietary supplements. This study investigated the influence of dietary fat and an emulsified delivery vehicle on CBG pharmacokinetics (PKs) after oral ingestion by adults. Materials and Methods: Consented participants were enrolled in a double-crossover pilot study and were blinded to the […]

    Læs mere
  • 27 maj
    Original: BMC Neurol .

    An observational time-series study on the behavioral effects of adjunctive artisanal cannabidiol use by adults with treatment resistant epilepsies

    Background: For approximately 30% of people with epilepsy, seizures are not well-controlled by anti-seizure medication (ASM). This condition, called treatment resistant epilepsy (TRE), is associated with increased morbidity and mortality, and substantially impacts the quality of life of both the individual and their family. Non-responsiveness to ASMs leads many people with TRE to seek alternative therapies, […]

    Læs mere
  • 26 maj
    Original: Chem Biol Interact .

    Decoding epilepsy treatment: A comparative evaluation contrasting cannabidiol pharmacokinetics in adult and paediatric populations

    Epilepsy is a neurological disorder characterized by overstimulation of neurotransmitters and uncontrolled seizures. Current medications for epilepsy result in adverse effects or insufficient seizure control, highlighting the necessity to develop alternative therapies. Cannabidiol (CBD), derived from cannabis plants, has been popularly explored as an alternative. CBD is shown to have anti-convulsivatng and muscle-relaxing properties, which […]

    Læs mere
  • 26 maj
    Original: Evid Based Dent .

    Cannabidiol – an effective analgesic for toothache?

    Design: The study by Chrepa et al. is a randomised, placebo-controlled, triple-arm, phase IIA clinical trial with double masking which investigates the effectiveness and safety of Cannabidiol (CBD) as an analgesic for acute dental pain. The intervention drug, Epidiolex is an FDA-approved CBD oral solution (100 mg/ml) derived from the cannabis plant. The psychoactive ingredient tetrahydrocannabinol […]

    Læs mere
  • 26 maj
    Original: CNS Drugs .

    Oral Delta-9-Tetrahydrocannabinol (THC) Increases Parasympathetic Activity and Supraspinal Conditioned Pain Modulation in Chronic Neuropathic Pain Male Patients: A Crossover, Double-Blind, Placebo-Controlled Trial

    Background: Disordered autonomic nervous system regulation and supraspinal pain inhibition have been repeatedly described in chronic pain. We aimed to explore the effects of δ-9-tetrahydrocannabinol (THC), an emerging treatment option, on autonomic nervous system and central pain modulation measures in patients with chronic pain. Methods: Twelve male patients with chronic radicular neuropathic pain participated in a randomized, […]

    Læs mere
  • 26 maj
    Original: Cannabis Cannabinoid Res .

    Endocannabinoids and Stress-Related Neurospsychiatric Disorders: A Systematic Review and Meta-Analysis of Basal Concentrations and Response to Acute Psychosocial Stress

    Background: Dysregulation of the endocannabinoid (eCB) system is implicated in various stress-related neuropsychiatric disorders (SRDs), including anxiety, depression, and post-traumatic stress disorder (PTSD). In this systematic review and meta-analysis, our objectives were to characterize circulating anandamide (AEA) and 2-arachidonoylglycerol (2-AG) concentrations at rest and in response to acute laboratory-based psychosocial stress in individuals with SRDs and […]

    Læs mere
  • 26 maj
    Original: Int J Mol Sci .

    Heteromers Formed by GPR55 and Either Cannabinoid CB1 or CB2 Receptors Are Upregulated in the Prefrontal Cortex of Multiple Sclerosis Patients

    Multiple sclerosis (MS) is an autoimmune, inflammatory, and neurodegenerative disease of the central nervous system for which there is no cure, making it necessary to search for new treatments. The endocannabinoid system (ECS) plays a very important neuromodulatory role in the CNS. In recent years, the formation of heteromers containing cannabinoid receptors and their up/downregulation […]

    Læs mere
  • 24 maj
    Original: Cannabis Cannabinoid Res .

    Comparative Pharmacokinetic Assessment of Innovative Sublingual, Rectal and Vaporizer Cannabis Products Versus Approved Cannabis Products in Healthy Volunteers

    Background: Over the last years, there is a dramatic increase in the use of medical cannabis products for an expanding range of clinical indications. The type of the drug product and its administration route affect substantially the rate and the extent of absorption of cannabinoids and the effects induced by them in the patients. The current […]

    Læs mere
  • 24 maj
    Original: Mayo Clin Proc .

    A Cross-Sectional Survey Study of Cannabis Use for Fibromyalgia Symptom Management

    Objective: To assess the use of cannabis as a symptom management strategy for patients with fibromyalgia. Patients and methods: An electronic, cross-sectional survey was conducted among patients diagnosed with fibromyalgia and treated in Integrative Medicine & Health at Mayo Clinic, Rochester, Minnesota. The survey was constructed with the Symptom Management Theory tool and was sent anonymously via […]

    Læs mere
  • 24 maj
    Original: J Pain .

    Interactions Between Endocannabinoid and Endogenous Opioid Systems Prospectively Influence Postoperative Opioid Use in Pregnant Patients Undergoing Cesarean Delivery

    Both endocannabinoid (EC) and endogenous opioid systems are involved in nociceptive processing and may work together synergistically based on preclinical models. This study evaluated the interactive effects of preoperative beta-endorphin (BE) concentrations (a key analgesic endogenous opioid) in cerebrospinal fluid (CSF) and ECs (CSF and plasma 2-arachidonoylglycerol and plasma anandamide) on postoperative opioid use and […]

    Læs mere
  • 24 maj
    Original: Neurodegener Dis Manag .

    Medicinal cannabis in neurodegenerative disorders: an open label, dose finding, safety and efficacy study

    Aim: Currently, there exist no curative treatments for neurodegenerative disorders. Recently, there has been a resurgence of interest in the use of medicinal cannabis to improve neurological conditions. Methods: A 12-month, open label, dose-finding, safety and efficacy study was conducted including 48 subjects with a variety of neurodegenerative disorders. Results: In our participants, we observed a reduction in pain, improved […]

    Læs mere
  • 24 maj
    Original: Int J Mol Sci .

    Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use

    Phytocannabinoids, a diverse group of naturally occurring compounds extracted from the Cannabis plant, have attracted interest due to their potential pharmacological effects and medicinal uses. This comprehensive review presents the intricate pharmacological profiles of phytocannabinoids while exploring the diverse impacts these substances have on biological systems. From the more than one hundred cannabinoids which were identified in […]

    Læs mere
  • 24 maj
    Original: Pain Ther .

    The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder

    This narrative review explores current insights into the potential use of medicinal cannabis-related products as an emerging therapy for opioid use disorder in the landscape of increasing knowledge about medicinal cannabis-based products, commercialisation and global legalisation. Preclinical studies have provided preliminary insight into the putative neurobiological mechanisms that underpin the potential for medicinal cannabis to […]

    Læs mere
  • 24 maj
    Original: Curr Pain Headache Rep .

    Cannabinoids for Acute Pain Management: Approaches and Rationale

    Purpose of the review: Acute pain management remains a challenge and postoperative pain is often undermanaged despite many available treatment options, also including cannabinoids. Recent findings: In the light of the opioid epidemic, there has been growing interest in alternative care bundles for pain management, including cannabinoids as potential treatment to decrease opioid prescribing. Despite the lack […]

    Læs mere
  • 24 maj
    Original: Paediatr Child Health .

    Medical cannabis for children: Evidence and recommendations

    Interest in using cannabis products for a medical purpose in children under the age of 18 years is increasing. There are many medical cannabis products available that can include cannabidiol (CBD) or delta-9-tetrahydrocannabinol (THC), or both. Despite many therapeutic claims, there are few rigorous studies to inform the dosing, safety, and efficacy of medical cannabis […]

    Læs mere
  • 24 maj
    Original: Neural Regen Res .

    Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies

    Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a variety of effects in the human body. They have been studied in cellular and animal models as well as in human clinical trials for their therapeutic benefits in several human diseases. Some of these include central nervous system (CNS) diseases and dysfunctions such […]

    Læs mere
  • 16 maj
    Original: Epilepsy Behav .

    Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis

    Objective: This study aimed to evaluate the efficacy and safety of six new antiseizure medications (ASMs) for adjunctive treatment in adult patients with focal epilepsy and adolescents with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC). Methods: A comprehensive literature search was performed using PubMed, Medline, Embase, and Cochrane library databases from inception to […]

    Læs mere
  • 16 maj
    Original: Curr Pain Headache Rep .

    Phytocannabinoids for the Treatment of Neuropathic Pain: A Scoping Review of Randomised Controlled Trials Published Between 2012 and 2023

    Purpose of review: Neuropathic pain (NP) remains a challenge to treat, with 50% of patients experiencing limited efficacy from current treatments. Medicinal cannabis, which contains tetrahydrocannabinol (THC), cannabidiol (CBD) and other minor cannabinoids, is garnering attention as an alternative treatment for NP. This paper reviews the clinical evidence for phytocannabinoid treatment of NP. Recent findings: Seventeen randomised […]

    Læs mere
  • 16 maj
    Original: J Dent Res

    Cannabidiol as an Alternative Analgesic for Acute Dental Pain

    Odontogenic pain can be debilitating, and nonopioid analgesic options are limited. This randomized placebo-controlled clinical trial aimed to assess the effectiveness and safety of cannabidiol (CBD) as an analgesic for patients with emergency acute dental pain. Sixty-one patients with moderate to severe toothache were randomized into 3 groups: CBD10 (CBD 10 mg/kg), CBD20 (CBD 20 […]

    Læs mere
  • 16 maj
    Original: J Cannabis Res .

    Neuroimaging studies of cannabidiol and potential neurobiological mechanisms relevant for alcohol use disorders: a systematic review

    The underlying neurobiological mechanisms of cannabidiol’s (CBD) management of alcohol use disorder (AUD) remains elusive. Aim We conducted a systematic review of neuroimaging literature investigating the efects of CBD on the brain in healthy participants. We then theorise the potential neurobiological mechanisms by which CBD may ameliorate various symptoms of AUD. Methods This review was […]

    Læs mere
  • 16 maj
    Original: Eur J Med Res

    The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials

    Background: Dravet Syndrome (DS) is a rare and severe form of childhood epilepsy that is often refractory to conventional antiepileptic drugs. Emerging evidence suggests that Cannabidiol (CBD) offer therapeutic benefits for DS. This review aims to evaluate the efficacy and safety of CBD in pediatric patients with DS based on data from ten clinical trials. Methods: A […]

    Læs mere
  • 16 maj
    Original: Anticancer Res .

    Cannabinoids for Cancer-related Pain Management: An Update on Therapeutic Applications and Future Perspectives

    Pain is a debilitating phenomenon that dramatically impairs the quality of life of patients. Many chronic conditions, including cancer, are associated with chronic pain. Despite pharmacological efforts that have been conducted, many patients suffering from cancer pain remain without treatment. To date, opioids are considered the preferred therapeutic choice for cancer-related pain management. Unfortunately, opioid […]

    Læs mere
  • 16 maj
    Original: CNS Drugs

    Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis

    Multiple sclerosis is a chronic inflammatory disease that affects the central nervous system and can cause various types of pain including ongoing extremity pain, Lhermitte’s phenomenon, trigeminal neuralgia, and mixed pain. Neuropathic pain is a major concern for individuals with multiple sclerosis as it is directly linked to myelin damage in the central nervous system […]

    Læs mere
  • 16 maj
    Original: Expert Opin Investig Drugs

    Early investigational agents for the treatment of benign prostatic hyperplasia

    Introduction: Benign prostatic hyperplasia (BPH), as a clinical entity that affects many people, has always been in the forefront of interest among researchers, pharmaceutical companies, and physicians. Patients with BPH exhibit a diverse range of symptoms, while current treatment options can occasionally cause adverse events. All the aforementioned have led to an increased demand for more […]

    Læs mere
  • 16 maj
    Original: J. Clin. Med.

    Δ9-Tetrahydrocannabinol (THC): A Critical Overview of Recent Clinical Trials and Suggested Guidelines for Future Research

    In this overview, we seek to appraise recent experimental and observational studies investigating THC and its potential role as adjunctive therapy in various medical illnesses. Recent clinical trials are suggestive of the diverse pharmacologic potentials for THC but suffer from small sample sizes, short study duration, failure to address tolerance, little dose variation, ill-defined outcome […]

    Læs mere
  • 16 maj
    Original: Behav Neurol .

    Amyotrophic Lateral Sclerosis and Pain: A Narrative Review from Pain Assessment to Therapy

    Amyotrophic lateral sclerosis (ALS) is the most frequent neurodegenerative disease of the motor system that affects upper and lower motor neurons, leading to progressive muscle weakness, spasticity, atrophy, and respiratory failure, with a life expectancy of 2-5 years after symptom onset. In addition to motor symptoms, patients with ALS have a multitude of nonmotor symptoms; […]

    Læs mere
  • 16 maj
    Original: Pharmaceutics

    CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

    Cannabinoid use has surged in the past decade, with a growing interest in expanding cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) applications into special populations. Consequently, the increased use of CBD and THC raises the risk of drug–drug interactions (DDIs). Nevertheless, DDIs for cannabinoids, especially in special populations, remain inadequately investigated. While some clinical trials have explored […]

    Læs mere
  • 16 maj
    Original: International Journal of Molecular Sciences

    Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition

    The post-COVID condition (PCC) is a pathology stemming from COVID-19, and studying its pathophysiology, diagnosis, and treatment is crucial. Neuroinflammation causes the most common manifestations of this disease including headaches, fatigue, insomnia, depression, anxiety, among others. Currently, there are no specific management proposals; however, given that the inflammatory component involves cytokines and free radicals, these […]

    Læs mere
  • 16 maj
    Original: Basic & Clinical Pharmacology & Toxicology

    Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson’s disease and in comorbidity with psychiatric disorders

    Studies have demonstrated the neuroprotective effect of cannabidiol (CBD) and other Cannabis sativa L. derivatives on diseases of the central nervous system caused by their direct or indirect interaction with endocannabinoid system-related receptors and other molecular targets, such as the 5-HT1A receptor, which is a potential pharmacological target of CBD. Interestingly, CBD binding with the 5-HT1A receptor may be […]

    Læs mere
  • 16 maj
    Original: Movement disorders

    Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson’s Disease: A Randomized Trial

    Background Cannabis use is frequent in Parkinson’s disease (PD), despite inadequate evidence of benefits and risks. Objective The aim is to study short-term efficacy and tolerability of relatively high cannabidiol (CBD)/low Δ-9-tetrahydrocannabinol (THC) to provide preliminary data for a longer trial. Methods Persons with PD with ≥20 on motor Movement Disorder Society Unified Parkinson’s Disease […]

    Læs mere
  • 16 maj
    Original: Experimental Dermatology

    Cannabinoids for the treatment of autoimmune and inflammatory skin diseases: A systematic review

    In recent years, the medical use of cannabinoids has attracted growing attention worldwide. In particular, anti-inflammatory properties of cannabinoids led to their emergence as potential therapeutic options for autoimmune and inflammatory disorders. Recent studies have also shown that cannabinoid receptors are widely expressed and have endogenous ligands in the skin, suggesting that the skin has […]

    Læs mere
  • 16 maj
    Original: European Neuropsychopharmacology

    A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood

    As cannabinoid-based medications gain popularity in the treatment of refractory medical conditions, it is crucial to examine the neurocognitive effects of commonly prescribed products to ensure associated safety profiles. The present study aims to investigate the acute effects of a standard 1 mL sublingual dose of CannEpil®, a medicinal cannabis oil containing 100 mg cannabidiol […]

    Læs mere
  • 16 maj
    Original: Industrial Crops and Products

    Health benefits, pharmacological properties, and metabolism of cannabinol: A comprehensive review

    Cannabinol (CBN) is a non-psychoactive phytocannabinoid found in Cannabis sativa. Although overshadowed by its more well-known counterparts, such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), CBN has been gaining attention due to its potential therapeutic properties. This review aims to provide insight into the molecular mechanisms underlying the pharmacological actions of CBN. CBN interacts with the endocannabinoid […]

    Læs mere
  • 19 apr
    Original: Maturitas

    Does medicinal cannabis affect depression, anxiety, and stress in people with cancer? A systematic review and meta-analysis of intervention studies

    Introduction Medicinal cannabis might have a role in supporting the mental health of people with cancer. This systematic review and meta-analysis examined the efficacy and safety of medicinal cannabis, compared with any control, as an intervention for depression, anxiety, and stress symptoms in people living with cancer. A secondary aim was to examine the effect […]

    Læs mere
  • 19 apr
    Original: Brain and behaviour

    UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia

    Introduction The primary aim of this study was to assess changes in sleep-specific health-related quality of life (HRQoL) for those prescribed cannabis-based medicinal products (CBMPs) for insomnia. Methods A case series of UK patients with insomnia was analyzed. Primary outcomes were changes in the Single-Item Sleep-Quality Scale (SQS), Generalized Anxiety Disorder-7 (GAD-7), and EQ-5D-5L at […]

    Læs mere
  • 19 apr
    Original: Children (Basel, Switzerland)

    The Use of Cannabinoids in Pediatric Palliative Care-A Retrospective Single-Center Analysis

    This data analysis aimed to systematically analyze a pediatric patient population with a life-limiting disease who were administered cannabinoids. It was a retrospective single-center analysis of patients under supervision of the specialized outpatient pediatric palliative care (SOPPC) team at the Department of Pediatrics and Adolescent Medicine of the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU). Thirty-one patients with a […]

    Læs mere
  • 19 apr
    Original: Neurodegenerative disease management

    Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures

    Aim: This prospective, multicenter, open-label, noninterventional 12-week study investigated the effectiveness and tolerability of add-on nabiximols oromucosal spray (Sativex®) in the real-world setting in Germany. Patients & methods: The main analysis set comprised 51 adult patients (49 nabiximols responders) with multiple sclerosis (MS) spasticity. Results: The mean overall goal attainment scale score (primary outcome measure) […]

    Læs mere
  • 19 apr
    Original: European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society

    Real life retrospective study of cannabidiol therapy in alternating hemiplegia of childhood

    Background: Many alternating hemiplegia of childhood (AHC) patients have received Cannabidiol (CBD) but, to our knowledge, there are no published data available. Goals: Test the hypothesis that CBD has favorable effects on AHC spells. Methods: Retrospective review of available data of AHC patients who received CBD. Primary analysis: Clinical Global Impression Scale of Improvement (CGI-I) […]

    Læs mere
  • 19 apr
    Original: International journal of molecular sciences

    Peripheral Endocannabinoid Components and Lipid Plasma Levels in Patients with Resistant Migraine and Co-Morbid Personality and Psychological Disorders: A Cross-Sectional Study

    Resistant migraine characterizes those patients who have failed at least three classes of migraine prophylaxis. These difficult-to-treat patients are likely to be characterized by a high prevalence of psychological disturbances. A dysfunction of the endocannabinoid system (ECS), including alteration in the levels of endocannabinoid congeners, may underlie several psychiatric disorders and the pathogenesis of migraines. […]

    Læs mere
  • 19 apr
    Original: Current opinion in pharmacology

    Targeting the endocannabinoid system for the management of low back pain

    Low back pain (LBP) is a major unmet clinical need. The endocannabinoid system (ECS) has emerged as a promising therapeutic target for pain, including LBP. This review examines the evidence for the ECS as a therapeutic target for LBP. While preclinical studies demonstrate the potential of the ECS as a viable therapeutic target, clinical trials […]

    Læs mere
  • 19 apr
    Original: Orthopaedic journal of sports medicine

    Cannabidiol for Postoperative Pain Control After Arthroscopic Rotator Cuff Repair Demonstrates No Deficits in Patient-Reported Outcomes Versus Placebo: 1-Year Follow-up of a Randomized Controlled Trial

    Background: Cannabidiol (CBD) has been shown recently to positively affect patient pain and satisfaction immediately after arthroscopic rotator cuff repair (ARCR). However, it is unclear whether the addition of CBD to a perioperative regimen could affect postoperative outcomes. Purpose: To evaluate patient-reported outcomes among patients who underwent ARCR and received buccally absorbed CBD or an […]

    Læs mere
  • 19 apr
    Original: Contemporary clinical trials communications

    Enhancing massed prolonged exposure with cannabidiol to improve posttraumatic stress disorder: Design and methodology of a pilot randomized clinical trial

    Background: The impact of posttraumatic stress disorder (PTSD) is substantial and often results in pervasive functional impairments. Although evidence-based treatments for PTSD are established, there remains room for improvement as many individuals continue to meet diagnostic criteria even after successful treatment completion. Cannabidiol (CBD) has attracted considerable attention based on its potential to treat a […]

    Læs mere
  • 19 apr
    Original: Journal of periodontal research

    Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol

    Objective: The aim of this study was to: (1) evaluate the anti-inflammatory effects of cannabidiol (CBD) on primary cultures of human gingival fibroblasts (HGFs) and (2) to clinically monitor the effect of CBD in subjects with periodontitis. Background: The use of phytocannabinoids is a new approach in the treatment of widely prevalent periodontal disease. Materials […]

    Læs mere
  • 19 apr
    Original: Pain management

    Pain management for post-treatment survivors of complex cancers: a qualitative study of opioids and cannabis

    Aim: We aimed to understand experiences with opioids and cannabis for post-treatment cancer survivors. Patients & methods: We conducted seven focus groups among head and neck and lung cancer survivors, using standard qualitative methodology to explore themes around 1) post-treatment pain and 2) utilization, perceived benefits and perceived harms of cannabis and opioids. Results & […]

    Læs mere
  • 19 apr
    Original: Drugs in context

    Effect of nabiximols oromucosal spray (Sativex®) on symptoms associated with multiple sclerosis-related spasticity: a case series

    Spasticity and its related symptoms of spasms, pain, sleep disturbance and bladder dysfunction are common in persons with multiple sclerosis (MS) and may be interconnected through a common pathophysiology and/or may trigger and worsen each other. Tetrahydrocannabinol-cannabidiol (nabiximols) oromucosal spray (Sativex) is an add-on treatment for adults with moderate-to-severe MS spasticity who fail to respond […]

    Læs mere
  • 19 apr
    Original: Developmental medicine and child neurology

    State-of-the-art therapies for fragile X syndrome

    Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by a full mutation (> 200 CGG repeats) in the FMR1 gene. FXS is the leading cause of inherited intellectual disabilities and the most commonly known genetic cause of autism spectrum disorder. Children with FXS experience behavioral and sleep problems, anxiety, inattention, learning difficulties, and speech […]

    Læs mere
  • 19 apr
    Original: Pharmacological research

    Novel rapid treatment options for adolescent depression

    There is an urgent need for novel fast-acting antidepressants for adolescent treatment-resistant depression and/or suicidal risk, since the selective serotonin reuptake inhibitors that are clinically approved for that age (i.e., fluoxetine or escitalopram) take weeks to work. In this context, one of the main research lines of our group is to characterize at the preclinical […]

    Læs mere
  • 19 apr
    Original: Journal of aging and health

    Cannabis Perceptions and Patterns of Use Among Older Adult Cancer Survivors

    Objectives: To descriptively assess cannabis perceptions and patterns of use among older adult cancer survivors in a state without a legal cannabis marketplace. Methods: This study used weighted prevalence estimates to cross-sectionally describe cannabis perceptions and patterns of use among older (65+) adults (N = 524) in a National Cancer Institute-designated center in a state […]

    Læs mere
  • 19 apr
    Original: medRxiv : the preprint server for health sciences

    Vaporized Cannabis versus Placebo for Acute Migraine: A Randomized Controlled Trial

    Background: Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine. Methods: In this randomized, double-blind, placebo-controlled, crossover trial, adults with migraine treated up to 4 separate migraine attacks, 1 each with vaporized 1) 6% Δ9-tetrahydrocannabinol (THC-dominant); […]

    Læs mere
  • 19 apr
    Original: International journal of molecular sciences

    The Role of Cannabidiol in Liver Disease: A Systemic Review

    Cannabidiol (CBD), a non-psychoactive phytocannabinoid abundant in Cannabis sativa, has gained considerable attention for its anti-inflammatory, antioxidant, analgesic, and neuroprotective properties. It exhibits the potential to prevent or slow the progression of various diseases, ranging from malignant tumors and viral infections to neurodegenerative disorders and ischemic diseases. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known […]

    Læs mere
  • 19 apr
    Original: Health science reports

    The effect of cannabinoids on wound healing: A review

    Background and aims: Cannabis and its various derivatives are commonly used for both recreational and medicinal purposes. Cannabinoids have been shown to have anti-inflammatory properties. Inflammation is an important component of wound healing and the effect of cannabinoids on wound healing has become a recent topic of investigation. The objective of this article is to […]

    Læs mere
  • 4 mar
    Original: BMC Med

    Dysfunction in endocannabinoids, palmitoylethanolamide, and degradation of tryptophan into kynurenine in individuals with depressive symptoms

    Background: The endocannabinoid (eCB) system and the serotonin (5-HT) are both implicated in the severity of the depression. 5-HT is synthesized from the amino acid tryptophan (Trp), which is also a precursor for kynurenine (Kyn) whose production is increased at the expense of 5-HT in depressed patients. No clinical studies have investigated the crosstalk between the […]

    Læs mere
  • 4 mar
    Original: Med Cannabis Cannabinoids

    Pharmacokinetic Variability of Oral Cannabidiol and Its Major Metabolites after Short-Term High-Dose Exposure in Healthy Subjects

    Introduction: Cannabidiol (CBD) is a widely utilized nonpsychoactive cannabinoid available as a prescriptive drug treatment and over-the-counter supplement. In humans, CBD is metabolized and forms the major active metabolite 7-hydroxy-cannabidiol (7-OH-CBD), which is further metabolized to 7-carboxy-cannabidiol (7-COOH-CBD). In the current study, plasma concentrations of CBD, 7-OH-CBD, and 7-COOH-CBD were measured, and the potential influences of […]

    Læs mere
  • 4 mar
    Original: J Orthop Surg Res

    Perceptions in orthopedic surgery on the use of cannabis in treating pain: a survey of patients with spine pain (POSIT Spine)

    Background: Back pain is the leading cause of disability worldwide. Despite guidelines discouraging opioids as first-line treatment, opioids remain the most prescribed drugs for back pain. There is renewed interest in exploring the potential medical applications of cannabis, and with the recent changes in national legislation there is a unique opportunity to investigate the analgesic properties […]

    Læs mere
  • 4 mar
    Original: Seizure

    Purified cannabidiol as add-on therapy in children with treatment-resistant infantile epileptic spasms syndrome

    Objective: The aim of this study was to assess efficacy, safety, and tolerability of highly purified cannabidiol oil (CBD) as add-on therapy for the treatment of a series of patients with infantile epileptic spasms syndrome (IESS) who were resistant to antiseizure medications and ketogenic dietary therapy. Material and methods: We conducted a retrospective analysis of the medical […]

    Læs mere
  • 4 mar
    Original: Pediatr Neurol .

    Real-Life Experience With Purified Cannabidiol Treatment for Refractory Epilepsy: A Multicenter Retrospective Study

    Background: Drug-resistant epilepsy (DRE) affects the development and quality of life of children and young adults. We analyzed the effectiveness and safety of purified CBD in this population. Methods: A retrospective analysis of medical records of 139 children and young adults (54.7% female, median age 12.0 years) with DRE treated with purified CBD from 2018 to 2022 […]

    Læs mere
  • 4 mar
    Original: Int J Gynecol Cancer

    Medical cannabis and its effect on oncological outcomes in patients with ovarian cancer treated with PARP inhibitors

    Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) play a pivotal role in ovarian cancer management. With medical cannabis emerging as a novel component of supportive care, this study investigated the impact of medical cannabis use on oncological outcomes in patients with ovarian cancer undergoing PARPi therapy. Methods: The study included patients from a single institution database treated for […]

    Læs mere
  • 4 mar
    Original: Journal of Anxiety Disorders

    Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data

    High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis […]

    Læs mere
  • 4 mar
    Original: BMJ Open

    Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials

    Objective: The objective of this study is to evaluate the comparative benefits and harms of opioids and cannabis for medical use for chronic non-cancer pain. Design: Systematic review and network meta-analysis. Data sources: EMBASE, MEDLINE, CINAHL, AMED, PsycINFO, PubMed, Web of Science, Cannabis-Med, Epistemonikos and the Cochrane Library (CENTRAL) from inception to March 2021. Study selection: Randomised trials comparing […]

    Læs mere
  • 4 mar
    Original: Cannabis Cannabinoid Res

    Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study

    Objective: Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have varying pharmacological actions with differential effects on acute and extended affective states, incuding anxiety. We aimed to study these effects on anxiety in legal market forms of cannabis. Method: This study makes use of a nonequivalent control group quasiexperimental design. Forty-two participants with anxiety symptions who were not using cannabis were […]

    Læs mere
  • 4 mar
    Original: Support Care Cancer

    Current cannabis use and pain management among US cancer patients

    Background: National studies reporting the prevalence of cannabis use have focused on individuals with a history of cancer without distinction by their treatment status, which can impact symptom burden. While pain is a primary motivation to use cannabis in cancer, the magnitude of its association with cannabis use remains understudied. Methods: We examined cannabis use and pain […]

    Læs mere
  • 4 mar
    Original: Expert Opin Emerg Drugs

    Cannabinoid treatment for the symptoms of autism spectrum disorder

    Introduction: Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting approximately 3% of school-age children. The core symptoms are deficits in social communication and restricted and repetitive patterns of behavior. Associated problems in cognition, language, behavior, sleep and mood are prevalent. Currently, no established pharmacological treatment exists for core ASD symptoms. Risperidone and aripiprazole are used […]

    Læs mere
  • 6 feb
    Original: Front Med

    Patients’ perspectives on prescription cannabinoid therapies: a cross-sectional, exploratory, anonymous, one-time web-based survey among German patients

    Introduction: Since cannabinoids were partially legalized as prescription medicines in Germany in 2017, they are mostly used when conventional therapies do not suffice. Ambiguities remain regarding use, benefits and risks. This web-based survey explored the perspectives of patients whose experiences are not well enough known to date. Methods: In an anonymous, exploratory, cross-sectional, one-time web-based observational study, […]

    Læs mere
  • 6 feb
    Original: Curr Pain Headache Rep

    Medical Cannabis and Its Efficacy/Effectiveness for the Treatment of Low-Back Pain: a Systematic Review

    Purpose of review: This systematic review aims to inform the current state of evidence about the efficacy and effectiveness of medical cannabis use for the treatment of LBP, specifically on pain levels and overall opioid use for LBP. Searches were conducted in MEDLINE (PubMed), Embase, and CINAHL. The search was limited to the past 10 years […]

    Læs mere
  • 6 feb
    Original: Dtsch Arztebl Int .

    Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs

    Background: Cannabinoid drugs containing tetrahydrocannabinol (THC), or its structural analogues, as monotherapeutic agents or as extracts or botanical preparations with or without cannabidiol (CBD) are often prescribed to multimorbid patients who are taking multiple drugs. This raises the question of the risk of drug interactions. Methods: This review of the pharmacokinetics and pharmacodynamics of interactions with cannabinoid […]

    Læs mere
  • 6 feb
    Original: Islets

    The function of the endocannabinoid system in the pancreatic islet and its implications on metabolic syndrome and diabetes

    The following review focuses on the scientific studies related to the role of endocannabinoid system (ECS) in pancreatic islet physiology and dysfunction. Different natural or synthetic agonists and antagonists have been suggested as an alternative treatment for diabetes, obesity and metabolic syndrome. Therapeutic use of Cannabis led to the discovery and characterization of the ECS, a signaling […]

    Læs mere
  • 6 feb
    Original: Physiol Res

    The Endocannabinoid System and Its Relationship to Human Reproduction

    The endocannabinoid system is among the most important regulators of human reproduction. It already applies at the level of the sperm and the egg, plays an important role in the fertilization of the egg, its implantation, regulates the function of the placenta and participates in childbirth. The aim of this work is to summarize the […]

    Læs mere
  • 2 feb
    Original: Anesthesia and analgesia

    Thoughtfully Integrating Cannabis Products Into Chronic Pain Treatment

    Cannabis products (CPs) and cannabis-based medicines (CBMs) are becoming increasingly available and are commonly used for pain management. The growing societal acceptance of cannabis and liberalization of cannabis laws allows patients to access CPs with minimal clinical oversight. While there is mechanistic plausibility that CPs and CBMs may be useful for pain management, the clinical […]

    Læs mere
  • 2 feb
    Original: Neuropsychopharmacology reports

    An observational study of clinical outcome measures in patients treated with cannabis-based medicinal products on the UK Medical Cannabis Registry

    Introduction: While there is increasing evidence of the effects of cannabis-based medicinal products (CBMPs) on health-related quality of life (HRQoL), a major limitation of the current literature is the heterogeneity of studied CBMPs. This study aims to analyze changes in HRQoL in patients prescribed a homogenous selection of CBMPs. Methods: Primary outcomes were changes in […]

    Læs mere
  • 2 feb
    Original: Current treatment options in oncology

    Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer – An Overview

    Pancreatic cancer (PC) remains the deadliest cancer worldwide. Most patients are diagnosed at the advanced or metastatic stage, leading to a poor prognosis. Awareness of the limitations of current therapy and accompanying pain, depression, malnutrition, and side effects of chemoradiotherapy may lead patients and physicians towards complementary and alternative medicine (CAM). CAM refers to a […]

    Læs mere
  • 2 feb
    Original: Molecular genetics and metabolism reports

    Relief of nocturnal neuropathic pain with the use of cannabis in a patient with Fabry disease

    Neuropathic pain is one of the most invalidating symptoms in patients with Fabry disease (FD), affecting their quality of life, it is linked to small fiber neuropathy and it may not respond to available disease specific treatments. We report the case of a 32 years old man with classic FD and severe neuropathic pain who, […]

    Læs mere
  • 2 feb
    Original: Neuropsychopharmacology reports

    A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance

    Background: Research on cannabis-based medicinal products (CBMPs) in anxiety remains inconclusive due to a paucity of high-quality evidence. Studies indicate a bidirectional relationship between generalized anxiety disorder (GAD) and sleep disruption, but it is unclear how this affects CBMP treatment outcomes. This study aims to compare the patient-reported outcome measures (PROMs) of patients prescribed CBMPs […]

    Læs mere
  • 27 dec
    Original: J Int Soc Sports Nutr .

    A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS)

    Background: Cannabinoid-containing products are marketed to athletes as promoting recovery, in spite of a lack of data on their safety and effects. This randomized, double-blind, placebo-controlled, repeated-dose pilot study tested the safety, tolerability, and preliminary effects on recovery of a formulation containing cannabidiol (CBD; 35 mg), cannabigerol (CBG; 50 mg), beta caryophyllene (BCP; 25 mg), branched-chain […]

    Læs mere
  • 27 dec
    Original: Cancer

    Cannabinoids for symptom management in children with cancer: A systematic review and meta-analysis

    Background: Despite the widespread use of medical cannabis, little is known regarding the safety, efficacy, and dosing of cannabis products in children with cancer. The objective of this study was to systematically appraise the existing published literature for the use of cannabis products in children with cancer. Methods: This systematic review, registered with the International Prospective Register […]

    Læs mere
  • 27 dec
    Original: Addiction

    Birth, cognitive and behavioral effects of intrauterine cannabis exposure in infants and children: A systematic review and meta-analysis

    Background and Aims Δ9-tetrahydrocannabinol (THC), the principal psychoactive component of cannabis, has been implicated in affecting fetal neurodevelopment by readily crossing the placenta. However, little is known regarding the long-term effects of intrauterine cannabis exposure. This systematic review and meta-analysis synthesized prospective and cross-sectional human studies to measure the effects of intrauterine cannabis exposure on […]

    Læs mere
  • 27 dec
    Original: Drug and Alcohol Review

    Daily diary study of associations between alcohol, cannabis, co-use and sleep quality in individuals with intentions to use cannabis to cope with anxiety

    Introduction Sleep problems and anxiety conditions are common comorbidities and may be influenced by cannabis and alcohol use. This study examined daily within-person variation in subjective sleep quality among individuals with anxiety symptoms after cannabis or alcohol were used alone, and after co-use. Methods A total of 347 individuals with intentions to use cannabis to […]

    Læs mere
  • 27 dec
    Original: Food Science & Nutrition

    Prebiotics Plus Probiotics May Favorably Impact on Gut Permeability, Endocannabinoid Receptors, and Inflammatory Biomarkers in Patients with Coronary Artery Diseases: A Clinical Trial

    While gut-to-systemic translocation of pyrogenic endotoxin due to a leaky gut elicits systemic inflammation, at the intestine, the endocannabinoid system (eCB) also plays a major role in modulating the impact of gut dysbiosis on the host system. Therefore, we hypothesized that coadministration of prebiotic inulin with probiotics would improve the eCB system, gut microbial composition, […]

    Læs mere
  • 27 dec
    Original: Toxicologie Analytique et Clinique

    Drug interactions with Cannabis sativa: Mechanisms and clinical implication

    The therapeutic properties of cannabis have been recognized for thousands of years. The main active compounds in cannabis that have been scientifically proven to possess pharmacological properties are tetrahydrocannabinol (THC), cannabinol (CBN), and cannabidiol (CBD). Cannabinoids have been found to serve diverse functions in physiological processes and are recognized for their properties including but not limited to, appetite stimulation, pain relief, anticonvulsant effects, bronchodilation, sedation, hypnotic […]

    Læs mere
  • 27 dec
    Original: J Neural Transm

    Therapeutic use of medical Cannabis in neurological diseases: a clinical update

    The use of medical Cannabis has increased in recent years due to changing legal circumstances in many countries. Approval exists only for a few neurological conditions such as rare forms of epilepsy or spasticity in multiple sclerosis. Beyond that, however, medical Cannabis is used for a wide range of neurological conditions and symptoms. In Germany, […]

    Læs mere
  • 27 dec
    Original: The Journal of Bone and Joint Surgery

    Cannabinoids in Spine Surgery for Pain Relief and Recovery

    » Cannabinoids, such as D9-tetrahydrocannabinol and cannabidiol, interact with endocannabinoid receptors in the central nervous system and immune system, potentially offering pain relief. The entourage effect, resulting from the interaction of multiple cannabis components, may enhance therapeutic impact and efficacy, making them promising candidates for exploring pain relief in spine operations, known to be among […]

    Læs mere
  • 27 dec
    Original: BMJ Support Palliat Care

    Medical cannabis for refractory cancer-related pain in a specialised clinical service: a cross-sectional study

    Background and objectives: Cancer-related pain management in advanced stages presents a significant challenge that often requires a multidisciplinary approach. Although advancements in pharmacological and interventional therapies, a considerable number of patients still suffer from refractory pain, leading to unmet clinical needs. This study shares our experience with medical cannabis (MC) as a potential therapy for this […]

    Læs mere
  • 27 dec
    Original: Pain Manag Nurs

    Effectiveness of Cannabidiol to Manage Chronic Pain: A Systematic Review

    Objectives: Cannabidiol (CBD), a component in Cannabis, is used to treat seizures, anxiety, and pain. Little is known about how effectively CBD works in managing chronic pain, a condition characterized by discomfort that persists beyond 3-6 months or beyond expected normal healing. Therefore, this systematic review aimed to synthesize evidence on the effectiveness of CBD in […]

    Læs mere
  • 27 dec
    Original: Am J Hosp Palliat Care .

    Epub 2023 Feb 15. Patient Reported Outcomes Using Medical Cannabis for Managing Pain in Charcot-Marie-Tooth Disease

    Objective: Chronic pain is a major problem for patients with Charcot-Marie-Tooth (CMT) disease. This exploratory study examined patient reported efficacy of medical cannabis for pain management in this population. Methods: Participants (N = 56; 71.4% female; Age = 48.9, SD = 14.6; 48.5% CMT1) were recruited though the Hereditary Neuropathy Foundation. The online survey contained 52 multiple choice […]

    Læs mere
  • 27 dec
    Original: Am J Hosp Palliat Care

    Cannabis in Cancer Survivors Who Report High Impact Chronic Pain: Findings from a 1500+ Patient Survey

    Background: Chronic pain in cancer survivors negatively impacts quality of life. This study sought to investigate the relationship between high-impact chronic pain (HICP) — defined as chronic pain that limits life or work activities on most days or every day in the past 3 months — and cannabis in cancer survivors. Methods: An electronic survey was developed […]

    Læs mere
  • 27 dec
    Original: CNS Drugs

    A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance

    Background and objectives: Medical cannabis use is increasing in Australia and other jurisdictions, yet little is known about the effects of medical cannabis on cognitive function. Findings from studies of non-medical (‘recreational’) cannabis may not be applicable to patients using prescribed medical cannabis to manage a health condition. Methods: In this semi-naturalistic, open-label trial, patients with various […]

    Læs mere
  • 27 dec
    Original: J Cannabis Res

    The holistic effects of medical cannabis compared to opioids on pain experience in Finnish patients with chronic pain

    Background: Medical cannabis (MC) is increasingly used for chronic pain, but it is unclear how it aids in pain management. Previous literature suggests that MC could holistically alter the pain experience instead of only targeting pain intensity. However, this hypothesis has not been previously systematically tested. Method: A retrospective internet survey was used in a sample of […]

    Læs mere
  • 27 dec
    Original: J Psychopharmacol .

    The potential for medicinal cannabis to help manage challenging behaviour in people with intellectual disability: A perspective review

    Background: Around 2% of the population have intellectual disabilities. Over one-third people with intellectual disabilities (PwID) present with ‘challenging behaviour’, which nosologically and diagnostically is an abstract concept. Challenging behaviour is influenced by a range of bio-psycho-social factors in a population, which is unable to suitably comprehend and/or communicate concerns. This predisposes to poor health and […]

    Læs mere
  • 27 dec
    Original: Reg Anesth Pain Med .

    Association of cannabis use with patient-reported pain measures among adults with chronic pain in US states with medical cannabis programs

    Introduction: Most Americans live in a state that has legalized cannabis as a medical treatment for pain, but it is unclear how chronic pain intensity relates to cannabis use. Our objective was to examine the association between patient-reported pain measures and cannabis among adults with chronic pain. Methods: This cross-sectional study of a representative sample of adults […]

    Læs mere
  • 27 dec
    Original: Can J Psychiatry

    Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study

    Objective: The treatment of bipolar depression remains challenging due to the limited effective and safe therapeutic options available; thus, developing newer treatments that are effective and well tolerable is an urgent unmet need. The objective of the present trial was to test 150 to 300 mg/day of cannabidiol as an adjunctive treatment for bipolar depression. Method: A […]

    Læs mere
  • 27 dec
    Original: J Dent Res

    Cannabidiol as an Alternative Analgesic for Acute Dental Pain

    Odontogenic pain can be debilitating, and nonopioid analgesic options are limited. This randomized placebo-controlled clinical trial aimed to assess the effectiveness and safety of cannabidiol (CBD) as an analgesic for patients with emergency acute dental pain. Sixty-one patients with moderate to severe toothache were randomized into 3 groups: CBD10 (CBD 10 mg/kg), CBD20 (CBD 20 […]

    Læs mere
  • 20 dec
    Original: Pharmaceutics .

    Development, Characterization and Pharmacological Evaluation of Cannabidiol-Loaded Long Circulating Niosomes

    Cannabidiol (CBD) is a promising drug candidate with pleiotropic pharmacological activity, whose low aqueous solubility and unfavorable pharmacokinetics have presented obstacles to its full clinical implementation. The rational design of nanocarriers, including niosomes for CBD encapsulation, can provide a plausible approach to overcoming these limitations. The present study is focused on exploring the feasibility of […]

    Læs mere
  • 20 dec
    Original: Epilepsy Behav .

    Highly purified cannabidiol in the treatment of drug-resistant epilepsies: A real-life impact on seizure frequency, quality of life, behavior, and sleep patterns from a single Italian center

    Seizure frequency in treatment-resistant epilepsies seems to be decreased by cannabidiol (CBD), but contrasting data are available on its effect on sleep, behavior, and quality of life (QoL), and no data is reported on its effect on parental stress in patients with epilepsy (PWE). Thus, we conducted a retrospective study on a cohort of children […]

    Læs mere
  • 20 dec
    Original: Exp Clin Psychopharmacol .

    A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality

    The present study sought to determine the effects of cannabinol (CBN) alone and in combination with cannabidiol (CBD) on sleep quality. This was a double-blind, randomized, placebo-controlled study conducted between May and November 2022. Participants were randomized to receive either (a) placebo, (b) 20 mg CBN, (c) 20 mg CBN + 10 mg CBD, (d) […]

    Læs mere
  • 20 dec
    Original: Br J Cancer .

    Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges

    The side effects of cancer therapy continue to cause significant health and cost burden to the patient, their friends and family, and governments. A major barrier in the way in which these side effects are managed is the highly siloed mentality that results in a fragmented approach to symptom control. Increasingly, it is appreciated that […]

    Læs mere
  • 20 dec
    Original: Rev Neurol

    High-purified cannabidiol efficacy and safety in a cohort of adult patients with various types of drug-resistant epilepsies

    About 30% of patients with epilepsy are drug resistant. Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) and tuberous sclerosis complex (TSC) are diseases for which high-purified-cannabidiol (CBD) known as Epidiolex® (GW pharma) can be prescribed in add-on of other medications in case of drug-resistance. Currently, there are only a few recent data in the literature about […]

    Læs mere
  • 20 dec
    Original: Rambam Maimonides Med J .

    Cannabis and Rheumatoid Arthritis: A Scoping Review Evaluating the Benefits, Risks, and Future Research Directions

    Rheumatoid diseases, including rheumatoid arthritis, osteoarthritis, and fibromyalgia, are characterized by progressive inflammation in the musculoskeletal system, predominantly affecting the joints and leading to cartilage and bone damage. The resulting pain and ongoing degradation of the musculoskeletal system contribute to reduced physical activity, ultimately impacting quality of life and imposing a substantial socioeconomic burden. Unfortunately, […]

    Læs mere
  • 4 dec
    Original: Seizure

    Real-world experience with cannabidiol as add-on treatment in drug-resistant epilepsy

    Purpose: To evaluate the efficacy and safety of cannabidiol (CBD) for the treatment of epilepsy in a real-world setting. Methods: In this retrospective observational study, we included PwE with epilepsy who received a prescription for CBD between 01.03.2019 and 30.11.2022 and had a follow-up period ≥ 3 months. Participants were evaluated at baseline and after […]

    Læs mere
  • 4 dec
    Original: Expert review of clinical pharmacology

    Challenges and considerations for treating PTSD with medicinal cannabis: the Australian clinician’s perspective

    Introduction: Preclinical and experimental research have provided promising evidence that medicinal cannabis may be efficacious in the treatment of posttraumatic stress disorder (PTSD). However, implementation of medicinal cannabis into routine clinical therapies may not be straightforward. Areas covered: In this review, we describe some of the clinical, practical, and safety challenges that must be addressed […]

    Læs mere
  • 4 dec
    Original: Supportive care in cancer

    Exploring potential anti-inflammatory effects of medicinal cannabis

    Purpose: Inflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer-related symptoms. Cannabidiol (CBD) is a bioactive compound in cannabis and is reported to have significant anti-inflammatory properties. Method: Serial C-reactive protein (CRP) levels were measured in all participants recruited to a randomised […]

    Læs mere
  • 4 dec
    Original: Journal of pain research

    Perceptions and Preoccupations of Patients and Physicians Regarding Use of Medical Cannabis as an Intervention Against Chronic Musculoskeletal Pain: Results from a Qualitative Study

    Objective: Explore perceptions and preoccupations regarding use of medical cannabis against chronic musculoskeletal pain, among patients and physicians. Design: Qualitative study using interviews with patients and physicians, based on the Theory of Planned Behavior (TPB). Setting: The study was conducted in Quebec, Canada, in spring 2020. Subjects: We included 27 adult patients and 11 physicians […]

    Læs mere
  • 4 dec
    Original: Drugs

    The Place of Cannabinoids in the Treatment of Gynecological Pain

    Cannabis sativa (L), a plant with an extensive history of medicinal usage across numerous cultures, has received increased attention over recent years for its therapeutic potential for gynecological disorders such as endometriosis, chronic pelvic pain, and primary dysmenorrhea, due at least in part to shortcomings with current management options. Despite this growing interest, cannabis inhabits […]

    Læs mere
  • 4 dec
    Original: Pediatric Annals

    Cannabidiol for the Treatment of Pediatric Epilepsy

    Pediatric epilepsy is a debilitating disease cluster that is much less researched than adult epilepsy. With approximately 30% of patients with pediatric epilepsy experiencing refractory seizures, novel treatment modalities are sometimes necessary to provide benefit. The use of marijuana, and more specifically cannabidiol, in people with seizures is much more broadly researched in adults compared […]

    Læs mere
  • 4 dec
    Original: Behavioural Neurology

    Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review

    Cannabidiol (CBD), derived from Cannabis sativa, has gained remarkable attention for its potential therapeutic applications. This thorough analysis explores the increasing significance of CBD in treating neurological conditions including epilepsy, multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease, which present major healthcare concerns on a worldwide scale. Despite the lack of available therapies, CBD has been […]

    Læs mere
  • 3 nov
    Original: Journal of neurochemistry

    Cannabis constituents for chronic neuropathic pain; reconciling the clinical and animal evidence

    Chronic neuropathic pain is a debilitating pain syndrome caused by damage to the nervous system that is poorly served by current medications. Given these problems, clinical studies have pursued extracts of the plant Cannabis sativa as alternative treatments for this condition. The vast majority of these studies have examined cannabinoids which contain the psychoactive constituent […]

    Læs mere
  • 3 nov
    Original: Operative techniques in orthopaedics

    Cannabinoids in Spine Surgery: A Comprehensive Review

    Cannabinoids have gained attention for their potential therapeutic effects in various fields, including pain control, augmenting fusion, neuroprotection, wound healing, inflammation, mental health, and clinical outcomes/complications. We explore the history and mechanism of action of cannabinoids, as well as their role in each of these areas. By examining existing research, the potential benefits and limitations […]

    Læs mere
  • 3 nov
    Original: Seizure: the journal of the British Epilepsy Association

    Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex

    Introduction: Highly purified cannabidiol (CBD) has a broad spectrum of action and could be useful for the treatment of drug resistant epilepsy regardless of etiology or syndrome. Materials and methods: Multicenter retrospective study that evaluated the efficacy and safety of CBD for the treatment of drug resistant epilepsy of different etiologies in patients >2 years […]

    Læs mere
  • 3 nov
    Original: Epilepsy & behavior: E&B

    Highly purified cannabidiol in the treatment of drug-resistant epilepsies: A real-life impact on seizure frequency, quality of life, behavior, and sleep patterns from a single Italian center

    Seizure frequency in treatment-resistant epilepsies seems to be decreased by cannabidiol (CBD), but contrasting data are available on its effect on sleep, behavior, and quality of life (QoL), and no data is reported on its effect on parental stress in patients with epilepsy (PWE). Thus, we conducted a retrospective study on a cohort of children […]

    Læs mere
  • 3 nov
    Original: Epilepsy & behavior: E&B

    Therapy outcomes associated with prescription cannabidiol use at 12 months post-initiation

    Objective This study evaluated prescription cannabidiol (CBD) outcomes during the first 12 months of therapy. Methods A single-center, prospective cohort study was performed including patients prescribed CBD from January 2019 – April 2020, excluding clinical trial patients and those using external specialty pharmacy services. The primary outcome wasepilepsy-related emergency healthcare service (EHS) use within 12 […]

    Læs mere
  • 3 nov
    Original: Therapeutic advances in neurological disorders

    A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols

    Background: Over 80% of individuals with multiple sclerosis (MS) experience MS-associated spasticity (MSS). In many European countries, after failure of first-line treatments, moderate or severe MSS can be treated with nabiximols, a cannabis-based add-on treatment. Objective: This post hoc analysis assessed the shift of participants treated with nabiximols from higher (severe or moderate) to lower […]

    Læs mere
  • 3 nov
    Original: JAAPA : official journal of the American Academy of Physician Assistants

    CBD oil. Your patients are using it. Here’s what you need to know

    Cannabinoid (CBD) oil is a trend in self-care management. In this digital age, patients have access to products from across the globe, and these products may not be regulated. Healthcare providers must be at the forefront of the latest trends in medicine and alternative therapies to better serve patients’ needs. This article reviews various medical […]

    Læs mere
  • 3 nov
    Original: Orphanet journal of rare diseases

    Integrative rare disease biomedical profile based network supporting drug repurposing or repositioning, a case study of glioblastoma

    Background: Glioblastoma (GBM) is the most aggressive and common malignant primary brain tumor; however, treatment remains a significant challenge. This study aims to identify drug repurposing or repositioning candidates for GBM by developing an integrative rare disease profile network containing heterogeneous types of biomedical data. Methods: We developed a Glioblastoma-based Biomedical Profile Network (GBPN) by […]

    Læs mere
  • 2 nov
    Original: Molecular psychiatry

    Exploring the influence of circulating endocannabinoids and nucleus accumbens functional connectivity on anorexia nervosa severity

    Anorexia nervosa (AN) is a severe psychiatric disorder characterized by a harmful persistence of self-imposed starvation resulting in significant weight loss. Research suggests that alterations in the nucleus accumbens (NAcc) and circulating endocannabinoids (eCBs), such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG), may contribute to increased severity and maladaptive behaviors in AN, warranting an examination of […]

    Læs mere
  • 2 nov
    Original: Drugs

    Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

    Background: Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized by drug-resistant, lifelong seizures. The management of seizures in DS has changed in recent years with the approval of new antiseizure medications (ASMs). Objective: The aim of this study was to estimate the comparative efficacy and tolerability of the ASMs for the treatment […]

    Læs mere
  • 2 nov
    Original: International journal of environmental research and public health

    An Individual’s Lived Experiences of Taking Cannabis-Based Medicinal Products (CBMPs) to Treat Anxiety

    This report documents the case of a patient (the author) participating in a clinical trial of medical cannabis (Cannabis sativa L.)—the Sapphire Access Scheme, run by the Sapphire Medical Clinic as part of the UK Medical Cannabis Registry—to explore the impacts of cannabis-based medicinal products (CBMPs) on anxiety. For most of my life, I have […]

    Læs mere
  • 2 nov
    Original: The journal of pharmacology and experimental therapeutics

    Role of cannabinoid signaling in cardiovascular function and ischemic injury

    Cardiovascular disease represents a leading cause of death, morbidity, and societal economic burden. The prevalence of cannabis use has significantly increased due to legalization and an increased societal acceptance of cannabis. Therefore, it is critically important that we gain a greater understanding of the effects and risks of cannabinoid use on cardiovascular diseases as well […]

    Læs mere
  • 2 nov
    Original: Journal of clinical gastroenterology

    Medical Cannabis Use Patterns and Adverse Effects in Inflammatory Bowel Disease

    Goals: To investigate medical cannabis (MC) use patterns and adverse effects in patients with inflammatory bowel disease (IBD). Background: MC is now legal in many states. Although previous studies suggest improvement in disease activity among IBD patients using MC, use patterns and adverse effects are unclear. Study: A cross-sectional anonymous survey was conducted (October 23, […]

    Læs mere
  • 2 nov
    Original: Nutrients

    Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity

    Background: The endocannabinoid system is active in nervous and immune cells and involves the expression of two cannabinoid receptor genes (CB1 and CB2), along with endogenous endocannabinoid ligands, 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide (anandamide), and their synthetic enzymes. Cannabidiol (CBD) is a non-intoxicating exogenous cannabinoid agonist derived from plants that, at high doses, has […]

    Læs mere
  • 2 nov
    Original: Addiction biology

    Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within-subject, randomized, placebo-controlled laboratory study

    The opioid and cannabinoid receptor systems are inextricably linked-overlapping at the anatomical, functional and behavioural levels. Preclinical studies have reported that cannabinoid and opioid agonists produce synergistic antinociceptive effects. Still, there are no experimental data on the effects of cannabinoid agonists among humans who receive opioid agonist therapies for opioid use disorder (OUD). We conducted […]

    Læs mere
  • 2 nov
    Original: The journal of clinical psychiatry

    The Use of Dispensary-Obtained Tetrahydrocannabinol as a Treatment for Neuropsychiatric Symptoms of Dementia

    Objective: Neuropsychiatric symptoms (NPS) of dementia represent a large driver of health care costs, caregiver burden, and institutionalization of people with dementia. Management options are limited, and antipsychotics are often used, although they carry a significant side effect profile. One novel option is tetrahydrocannabinol (THC); however, in the US, to obtain THC for patients with […]

    Læs mere
  • 2 nov
    Original: Cannabis and cannabinoid research

    Oral Cannabidiol Treatment in Two Postmenopausal Women with Osteopenia: A Case Series

    Introduction: Cannabidiol (CBD), a nonintoxicating cannabinoid, may be involved in bone remodeling, but human studies are limited. In this case series, we explored the effects of oral CBD administration on bone turnover. Materials and Methods: Two postmenopausal women with osteopenia (T-score=-1 to -2.5) were randomized to receive 100 or 300 mg CBD daily (oral, bis in die [twice per day]) […]

    Læs mere
  • 24 sep
    Original: NPJ Breast Cancer

    CBD-oil as a potential solution in case of severe tamoxifen-related side effects

    Tamoxifen may lead to bothersome side effects contributing to non-compliance and decreased quality of life. Patients searching for relief are increasingly turning to cannabinoids such as CBD-oil. However, CBD-oil might affect tamoxifen pharmacokinetics (PK) through CYP2D6 inhibition. The aims of this open-label, single-arm study were (1) to determine the PK profile of tamoxifen when using […]

    Læs mere
  • 24 sep
    Original: Front Psychiatry

    Individually tailored dosage regimen of full-spectrum Cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits

    Autism Spectrum Disorders (ASD) may significantly impact the well-being of patients and their families. The therapeutic use of cannabis for ASD has gained interest due to its promising results and low side effects, but a consensus on treatment guidelines is lacking. In this study, we conducted a retrospective analysis of 20 patients with autistic symptoms […]

    Læs mere
  • 24 sep
    Original: Epilepsia Open

    Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program

    Objective: The aim of this study was to assess potential drug-drug interactions between highly purified cannabidiol (CBD) and anti-seizure medications (ASMs). Methods: Our group previously reported that in a sample of adults and children receiving CBD in an open-label expanded access program, there were several ASMs noted to increase in serum levels with increasing doses of CBD. […]

    Læs mere
  • 24 sep
    Original: ACG CASE REPORTS JOURNAL

    Cannabis Improves Clinical Outcomes and Quality of Life in Patients With Chronic Pouchitis

    Many patients with ulcerative colitis after ileoanal pouch anastomosis report improvement of pouchitis with the use of cannabis. Nine patients with chronic pouchitis used 1 g/d of cannabis: 7 patients were male with average age 51 ± 16 years. Average partial pouchitis disease activity index were 11 (range 8-17), 6 (range 5-8), and 5 (range […]

    Læs mere
  • 24 sep
    Original: Am J Hematol

    Dramatic efficacy of cannabidiol on refractory chronic pain in an adolescent with sickle cell disease

    Here, we report a dramatic efficacy of cannabidiol in an adolescent with SCD suffering from chronic pain refractory to other analgesics, with complete regression of chronic pain and rapid plasma histamine level normalization after treatment.

    Læs mere
  • 24 sep
    Original: Cancer

    Cannabinoids for symptom management in children with cancer: A systematic review and meta-analysis

    Background: Despite the widespread use of medical cannabis, little is known regarding the safety, efficacy, and dosing of cannabis products in children with cancer. The objective of this study was to systematically appraise the existing published literature for the use of cannabis products in children with cancer. Methods: This systematic review, registered with the International Prospective Register […]

    Læs mere
  • 24 sep
    Original: Psychopharmacology

    The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial

    Rationale: Evidence suggests cannabidiol (CBD) displays broad therapeutic potential in the context of anxiety; however, no study has examined the effects of CBD on worry, a defining, cognitive feature of anxiety. Additionally, no study has examined the effects of an acute, single dose of CBD compared to repeated CBD administration. Objectives: Within a sample of 63 individuals […]

    Læs mere
  • 24 sep
    Original: Cancers

    Morphine Analgesia, Cannabinoid Receptor 2, and Opioid Growth Factor Receptor Cancer Tissue Expression Improve Survival after Pancreatic Cancer Surgery

    Pancreatic cancer (PDAC) has a poor prognosis despite surgical removal and adjuvant therapy. Additionally, the effects of postoperative analgesia with morphine and piritramide on survival among PDAC patients are unknown, as are their interactions with opioid/cannabinoid receptor gene expressions in PDAC tissue. Cancer-specific survival data for 71 PDAC patients who underwent radical surgery followed by […]

    Læs mere
  • 24 sep
    Original: J Infect Dis

    Impact of cannabis use on immune cell populations and the viral reservoir in people with HIV on suppressive antiretroviral therapy

    Background: HIV infection remains incurable due to the persistence of a viral reservoir despite antiretroviral therapy (ART). Cannabis (CB) use is prevalent amongst people with HIV (PWH), but the impact of CB on the latent HIV reservoir has not been investigated. Methods: Peripheral blood cells from a cohort of PWH who use CB and a matched cohort […]

    Læs mere
  • 24 sep
    Original: Ther Adv Neurol Disord

    Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies

    Developmental and epileptic encephalopathies (DEEs) are rare neurodevelopmental disorders characterised by early-onset and often intractable seizures and developmental delay/regression, and include Dravet syndrome and Lennox-Gastaut syndrome (LGS). Rufinamide, fenfluramine, stiripentol, cannabidiol and ganaxolone are antiseizure medications (ASMs) with diverse mechanisms of action that have been approved for treating specific DEEs. Rufinamide is thought to suppress […]

    Læs mere
  • 24 sep
    Original: International Journal of Women’s Health

    Oral Tetrahydrocannabinol (THC):Cannabinoid (CBD) Cannabis Extract Adjuvant for Reducing Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial

    Objective: To evaluate the effects of tetrahydrocannabinol (THC):cannabinoid (CBD) (1:1) oil in reducing chemotherapy-induced nausea and vomiting (CINV) in gynecologic cancer patients who received moderate-to-high emetogenic chemotherapy. Material and method: This was a randomized, double-blinded, crossover and placebo-controlled trial. The study was conducted at the Gynecologic Oncology Units, Bhumibol Adulyadej Hospital (BAH), Royal Thai Air Force, Bangkok, […]

    Læs mere
  • 24 sep
    Original: BMJ

    Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

    Objective: To systematically assess credibility and certainty of associations between cannabis, cannabinoids, and cannabis based medicines and human health, from observational studies and randomised controlled trials (RCTs). Design: Umbrella review. Data sources: PubMed, PsychInfo, Embase, up to 9 February 2022. Eligibility criteria for selecting studies: Systematic reviews with meta-analyses of observational studies and RCTs that have reported on the […]

    Læs mere
  • 24 sep
    Original: Phytother Res

    Association between cannabis use and risk of diabetes mellitus type 2: A systematic review and meta-analysis

    Background: Cannabis consumption exerts multiple effects on metabolism via various pathways, including glucose regulation and insulin secretion. Studies concerning the association between cannabis use and diabetes mellitus type 2 are discrepant. Objective: This study was conducted to evaluate the association between cannabis use and type 2 diabetes mellitus (T2DM). Search methods: We searched PubMed, Scopus, Embase, Proquest, Web […]

    Læs mere
  • 24 sep
    Original: Pharmaceuticals

    Therapeutic Potential of Cannabinoids in Glaucoma

    Glaucoma is a leading cause of irreversible blindness worldwide. To date, intraocular pressure (IOP) is the only modifiable risk factor in glaucoma treatment, but even in treated patients, the disease can progress. Cannabinoids, which have been known to lower IOP since the 1970s, have been shown to have beneficial effects in glaucoma patients beyond their […]

    Læs mere
  • 21 aug
    Original: Der Schmerz

    Tetrahydrocannabinol (THC) bei Patienten mit Fibromyalgiesyndrom (FMS)

    Background Since March 1, 2017, medical cannabis (MC) can be prescribed nationwide in Germany. To date, there have been a number of qualitatively different studies on the effectiveness of MC in fibromyalgia syndrome (FMS). Objective The aim of the study was to investigate the effectiveness of THC in the course of interdisciplinary multimodal pain therapy (IMPT) on […]

    Læs mere
  • 21 aug
    Original: Psychopharmacology

    Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry

    Rationale Cannabis-based medicinal products (CBMPs) have been identified as novel therapeutics for generalised anxiety disorder (GAD) based on pre-clinical models; however, there is a paucity of high-quality evidence on their effectiveness and safety. Objectives This study aimed to evaluate the clinical outcomes of patients with GAD treated with dried flower, oil-based preparations, or a combination […]

    Læs mere
  • 21 aug
    Original: Journal of Ethnopharmacology

    Natural product-derived therapies for treating drug-resistant epilepsies: From ethnopharmacology to evidence-based medicine

    Ethnopharmacological relevance Epilepsy is one of the most prevalent neurological human diseases, affecting 1% of the population in all age groups. Despite the availability of over 25 anti-seizure medications (ASMs), which are approved in most industrialized countries, approximately 30% of epilepsy patients still experience seizures that are resistant to these drugs. Since ASMs target only […]

    Læs mere
  • 21 aug
    Original: Rev Neurol .

    Use of psychoactive substances as a treatment for psychosis

    Introduction: Psychotic disorders are considered chronic mental health issues. Although it has been demonstrated that these disorders can present with a wide range of symptoms, pharmacological treatment is based on the use of typical and atypical antipsychotics, whose main mechanism of action is dopaminergic blockade, limiting their effect to the improvement of positive symptoms, without improving […]

    Læs mere
  • 21 aug
    Original: Biomedicines

    Cannabis for the Treatment of Fibromyalgia: A Systematic Review

    Fibromyalgia is a common disease syndrome characterized by chronic pain and fatigue in conjunction with cognitive dysfunction such as memory difficulties. Patients currently face a difficult prognosis with limited treatment options and a diminished quality of life. Given its widespread use and potential efficacy in treating other types of pain, cannabis may prove to be […]

    Læs mere
  • 21 aug
    Original: Expert Opinion on Pharmacotherapy

    Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome

    Introduction Lennox-Gastaut syndrome (LGS) is a severe childhood-onset epileptic encephalopathy, characterized by multiple seizure types, generalized slow spike-and-wave complexes in the EEG, and cognitive impairment. Seizures in LGS are typically resistant to treatment with antiseizure medications (ASMs). Tonic/atonic (‘drop’) seizures are of particular concern, due to their liability to cause physical injury. Areas covered We […]

    Læs mere
  • 21 aug
    Original: J Clin Psychopharmacol .

    Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers: A Pilot, Proof-of-Concept, Feasibility, Randomized-Controlled Trial

    Background: Serotonergic hallucinogens and cannabinoids may alter the recognition of emotions in facial expressions (REFE). Cannabidiol (CBD) attenuates the psychoactive effects of the cannabinoid-1 agonist tetrahydrocannabinol. Ayahuasca is a dimethyltryptamine-containing hallucinogenic decoction. It is unknown if CBD may moderate and attenuate the effects of ayahuasca on REFE. Procedures: Seventeen healthy volunteers participated in a 1-week preliminary parallel-arm, […]

    Læs mere
  • 21 aug
    Original: Advances in Therapy

    The Influence of Oral Cannabidiol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Untreated Hypertension: A Double-Blind, Placebo-Controlled, Cross-Over Pilot Study

    Introduction Studies reveal that cannabidiol may acutely reduce blood pressure and arterial stiffness in normotensive humans; however, it remains unknown if this holds true in patients with untreated hypertension. We aimed to extend these findings to examine the influence of the administration of cannabidiol on 24-h ambulatory blood pressure and arterial stiffness in hypertensive individuals. […]

    Læs mere
  • 21 aug
    Original: Front. Med

    Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin®) site pain: a case report

    Background: Pulmonary arterial hypertension occurs as a result of vascular remodeling and dysregulation of endothelial cells that narrows small pulmonary arteries and raises precapillary pressures. Pulmonary arterial hypertension is a rare and progressive disease characterized by dyspnea, chest pain, and syncope. Parenteral treprostinil is indicated for the treatment of pulmonary arterial hypertension to diminish symptoms associated […]

    Læs mere
  • 21 aug
    Original: Frontiers in Neurology

    A single-center real-life study on the use of medical cannabis in patients with dystonia

    Background: While cannabis-based medicine is being commonly used in patients with movement disorders, there is a scarcity of publications regarding the effect of cannabis on dystonia. We aimed to describe medical cannabis use in patients with dystonia and related pain. Methods: We employed a structured interview to obtain data on the cannabis treatment regimen, perception of effectiveness […]

    Læs mere
  • 21 aug
    Original: Cannabis and Cannabinoid Research

    Sex Differences in the Pharmacokinetics of Cannabidiol and Metabolites Following Oral Administration of a Cannabidiol-Dominant Cannabis Oil in Healthy Adults

    Introduction: Oral cannabidiol (CBD) product use is increasingly growing among women; however, there is a lack of data on sex differences in the pharmacokinetics (PKs) of CBD and its primary metabolites, 7-hydroxy-CBD (7-OH-CBD) and 7-carboxy-CBD (7-COOH-CBD), after repeated doses. Materials and Methods: The present study is a secondary analysis of data from a randomized, double-blind, placebo-controlled multiple-dose […]

    Læs mere
  • 21 aug
    Original: Cochrane Database of Systematic Reviews

    Cannabis-based medicines and medical cannabis for adults with cancer pain (Review)

    Background Pain is a common symptom in people with cancer; 30% to 50% of people with cancer will experience moderate-to-severe pain. This can have a major negative impact on their quality of life. Opioid (morphine-like) medications are commonly used to treat moderate or severe cancer pain, and are recommended for this purpose in the World […]

    Læs mere
  • 21 aug
    Original: Journal of Cannabis Research

    The therapeutic potential of purifed cannabidiol

    The use of cannabidiol (CBD) for therapeutic purposes is receiving considerable attention, with speculation that CBD can be useful in a wide range of conditions. Only one product, a purifed form of plant-derived CBD in solution (Epidiolex), is approved for the treatment of seizures in patients with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. […]

    Læs mere
  • 21 aug
    Original: Epilepsy & Behavior

    The use of cannabinoids in children with epilepsy: A systematic review

    Introduction Epileptic syndromes affecting children can sometimes be refractory to pharmacological treatments. Cannabinoids, especially cannabidiol, began to be studied to contribute to the treatment of these syndromes, configuring an expanding research area. The aim of this paper was to evaluate the scientific evidence available in the literature regarding the use of cannabinoids in the therapy […]

    Læs mere
  • 21 aug
    Original: Australasian Journal on Ageing

    Examining the use of cannabidiol and delta- 9- tetrahydrocannabinol- based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double- blind randomised crossover trial

    Objective Dementia affects individuals older than 65 years. Currently, residential aged care facilities (RACF) use psychotropic medications to manage behavioural and neuropsychiatric symptoms of dementia (BPSD), which are recommended for short-term use and have substantial side effects, including increased mortality. Cannabinoid-based medicines (CBM) have some benefits that inhibit BPSD and cause minimal adverse effects (AEs), yet […]

    Læs mere
  • 21 aug
    Original: Nutrients

    Alleviation of Pain, PAIN Interference, and Oxidative Stress by a Novel Combination of Hemp Oil, Calamari Oil, and Broccoli: A Randomized, Double-Blind, Placebo-Controlled Trial

    Chronic pain is a critical health issue in the US that is routinely managed pharmacologically with diminishing results. The widespread misuse and abuse of prescription opioid pain medications have caused both healthcare providers and patients to seek alternative therapeutic options. Several dietary ingredients have been traditionally used for pain relief and are known to have […]

    Læs mere
  • 20 aug
    Original: Journal of Cannabis Research

    Naturalistic examination of the anxiolytic effects of medical cannabis and associated gender and age differences in a Canadian cohort

    Background The aim of the current study was to examine patterns of medical cannabis use in those using it to treat anxiety and to investigate if the anxiolytic effects of cannabis were impacted by gender and/or age. Methods Patient-reported data (n = 184 participants, 61% female, 34.7 ± 8.0 years) was collected through the Strainprint® app. Tracked sessions were included […]

    Læs mere
  • 20 aug
    Original: J Clin Gastroenterol .

    The Impact of Chronic Cannabis Use on Esophageal Motility in Patients Referred for Esophageal Manometry

    Background: Tetrahydrocannabinol, the main psychoactive compound in cannabis, binds with high affinity to the cannabinoid 1 receptor. Small randomized controlled studies using conventional manometry have shown that the cannabinoid 1 receptor can modulate esophageal function, namely transient lower esophageal sphincter relaxation frequency and lower esophageal sphincter tone. The effect of cannabinoids on esophageal motility in patients […]

    Læs mere
  • 20 aug
    Original: Sociology of Health & Illness

    Quality of life beyond measure: Advanced cancer patients, wellbeing and medicinal cannabis

    Experiences of advanced cancer are assembled and (re)positioned with reference to illness, symptoms and maintaining ‘wellbeing’. Medical cannabis is situated at a borderline in this and the broader social domain: between stigmatised and normalised; recreational and pharmaceutical; between perception, experience, discourse and scientific proof of benefit. Yet, in the hyper-medicalised context of randomised clinical trials […]

    Læs mere
  • 23 jul
    Original: Int. J. Mol. Sci

    Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients

    We report the cases of two young German male patients with treatment-resistant Tourette syndrome (TS), who suffer from incapacitating stuttering-like speech disfluencies caused by vocal blocking tics and palilalia. Case 1: a 19-year old patient received medical cannabis at a dose of 1 × 0.1 g cannabis daily. Case 2: a 16-year old patient initially […]

    Læs mere
  • 23 jul
    Original: Clinical gerontologist

    The Effect of Cannabidiol 3% on Neuropsychiatric Symptoms in Dementia – Six-Month Follow-Up

    Objectives To investigate the beneficial outcomes of giving cannabidiol (CBD) 3% over a six-month period in the BPSD, the management of which is a crucial issue for everyday clinical praxis and to compare the progress in BPSD of patients who receive Cannabidiol 3% with those who follow usual medical treatment (UMT) in everyday clinical praxis. […]

    Læs mere
  • 23 jul
    Original: The Australian and New Zealand journal of psychiatry

    THE PROMISE OF THE THERAPEUTIC USE OF CANNABIDIOL FOR PSYCHIATRIC DISORDERS

    Læs mere
  • 23 jul
    Original: JAMA network open

    Assessment of Medical Cannabis and Health-Related Quality of Life

    Importance  The use of cannabis as a medicine is becoming increasingly prevalent. Given the diverse range of conditions being treated with medical cannabis, as well as the vast array of products and dose forms available, clinical evidence incorporating patient-reported outcomes may help determine safety and efficacy. Objective  To assess whether patients using medical cannabis report improvements in […]

    Læs mere
  • 23 jul
    Original: Experimental and clinical psychopharmacology

    Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric and neurological illness: A narrative review

    Cannabidiol (CBD) is one of the major phytocannabinoids present in the cannabis plant, with no acute psychotropic effects and a favorable safety and abuse liability profile. Animal and limited controlled human studies have demonstrated CBD to have analgesic, anxiolytic, anti-inflammatory, antipsychotic, and anticonvulsant effects, to name a few possible indications. There is growing evidence for […]

    Læs mere
  • 23 jul
    Original: Environmental research

    Therapeutic targeting of the tumor microenvironments with cannabinoids and their analogs: Update on clinical trials

    Cancer is a major global public health concern that affects both industrialized and developing nations. Current cancer chemotherapeutic options are limited by side effects, but plant-derived alternatives and their derivatives offer the possibilities of enhanced treatment response and reduced side effects. A plethora of recently published articles have focused on treatments based on cannabinoids and […]

    Læs mere
  • 23 jul
    Original: Cannabis and cannabinoid research

    CANNABINOIDS IN TREATING PARKINSON’S DISEASE SYMPTOMS: A SYSTEMATIC REVIEW OF CLINICAL STUDIES

    Background: Parkinson’s disease (PD) is a serious neurodegenerative condition impacting many individuals worldwide. There is a need for new non-invasive treatments of PD. Cannabinoids in the form of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may offer utility as treatment, and our objective was hence to conduct a systematic review regarding the clinical evidence for the efficacy and […]

    Læs mere
  • 23 jul
    Original: Orthopedics

    Orthopedics . 2023 May 23;1-5. doi: 10.3928/01477447-20230517-06. Online ahead of print. Cannabidiol Use Patterns and Efficacy for Children Who Have Cerebral Palsy

    Cannabidiol (CBD)-containing supplements are used by children with cerebral palsy (CP), but the prevalence and efficacy of their use have not been studied. We sought to describe CBD use patterns and perceived efficacy in the pediatric population with CP, evaluating any association between CBD use and health-related quality of life. Patients with CP were prospectively […]

    Læs mere
  • 23 jul
    Original: BMJ supportive & palliative care

    Medical cannabis is effective for cancer-related pain: Quebec Cannabis Registry results

    Objectives: To evaluate the safety and effectiveness of medical cannabis (MC) in reducing pain and concurrent medications in patients with cancer. Methods: This study analysed data collected from patients with cancer who were part of the Quebec Cannabis Registry. Brief Pain Inventory (BPI), revised Edmonton Symptom Assessment System (ESAS-r) questionnaires, total medication burden (TMB) and morphine equivalent […]

    Læs mere
  • 23 jul
    Original: American journal of therapeutics

    Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice-A Review

    Background: As far as 80% of people diagnosed with multiple sclerosis (MS) experience disabling symptoms in the course of the disease, such as spasticity and neuropathic pain. As first-line symptomatic therapy is associated with important adverse reactions, cannabinoids have become increasingly popular among patients with MS. This review intends to provide an overview of the evidence […]

    Læs mere
  • 23 jul
    Original: Journal of the American Nutrition Association

    The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial

    Background Clinical evidence on the use of cannabidiol (CBD) for sleep remains limited. Even fewer studies have tested the comparative effectiveness of cannabinoid formulations found within CBD products used for sleep or how they compare to other complementary therapies such as melatonin. Methods Participants (N = 1,793 adults experiencing symptoms of sleep disturbance) were randomly assigned to […]

    Læs mere
  • 23 jul
    Original: Injury

    Impact of cannabis on outcome in patients following traumatic injury

    Introduction Outcomes of trauma patients who tested positive for cannabis at the time of admission showed variable results. Sample size and research methodology that was used in prior studies may have resulted in the conflict. The purpose of the study was to evaluate the impact of cannabis use on outcomes in trauma patients using national […]

    Læs mere
  • 23 jul
    Original: Epilepsy & behavior: E&B

    Cannabidiol as an adjuvant treatment in adults with drug-resistant focal epilepsy

    Cannabidiol oil (CBD) has been approved as an anti-seizure medication for the treatment of uncommon types of epilepsy, occurring in children: Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex. There are few publications in relation to use the CBD in adult patients with focal drug-resistant epilepsy. The objective of this study was to evaluate the […]

    Læs mere
  • 23 jul
    Original: Journal of psychiatric research

    The impact of cannabidiol treatment on resting state functional connectivity, prefrontal metabolite levels and reward processing in recent-onset patients with a psychotic disorder

    The first clinical trials with cannabidiol (CBD) as treatment for psychotic disorders have shown its potential as an effective and well-tolerated antipsychotic agent. However, the neurobiological mechanisms underlying the antipsychotic profile of CBD are currently unclear. Here we investigated the impact of 28-day adjunctive CBD or placebo treatment (600 mg daily) on brain function and […]

    Læs mere
  • 23 jul
    Original: Epilepsy & behavior: E&B

    Cannabidiol in children with treatment-resistant epilepsy with myoclonic-atonic seizures

    Purpose: This multicenter study aimed to evaluate the efficacy and tolerability of add-on cannabidiol (CBD) in treatment-resistant patients with epilepsy with myoclonic-atonic seizures (EMAtS) (n = 22) and Sturge Weber syndrome (SWS) with myoclonic-atonic seizures (n = 4). Methods: Patients who met the diagnostic criteria of treatment-resistant EMAtS or SWS with myoclonic-atonic seizures were included. Cannabidiol was […]

    Læs mere
  • 23 jul
    Original: Seizure: the journal of the British Epilepsy Association

    Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome

    Purpose: This retrospective chart review study (GWEP20052) evaluated plant-derived highly purified cannabidiol (CBD; Epidyolex®; 100 mg/mL oral solution) use without clobazam as add-on therapy in patients aged ≥2 years with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) enrolled in a European Early Access Program. Methods: Data were extracted from patient charts covering a period starting 3 months […]

    Læs mere
  • 23 jul
    Original: Multiple sclerosis and related disorders

    Characterizing cannabis use in a sample of adults with multiple sclerosis and chronic pain: An observational study

    Background: Although cannabis has become an increasingly common method for pain management among people with multiple sclerosis (PwMS), there is a dearth of knowledge regarding the types of cannabis products used as well as the characteristics of cannabis users. The current study aimed to (1) describe the prevalence of cannabis use and the routes of administration […]

    Læs mere
  • 23 jul
    Original: Brain and behavior

    Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry

    There are limited therapeutic options for individuals with fibromyalgia. The aim of this study is to analyze changes in health-related quality of life and incidence of adverse events of those prescribed cannabis-based medicinal products (CBMPs) for fibromyalgia. Methods : Patients treated with CBMPs for a minimum of 1 month were identified from the UK Medical Cannabis […]

    Læs mere
  • 23 jul
    Original: Epilepsia

    Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program

    The cannabidiol (CBD) Expanded Access Program (EAP), initiated in 2014, provided CBD (Epidiolex) to patients with treatment-resistant epilepsy (TRE). In the final pooled analysis of 892 patients treated through January 2019 (median exposure = 694 days), CBD treatment was associated with a 46%-66% reduction in median monthly total (convulsive plus nonconvulsive) seizure frequency. CBD was […]

    Læs mere
  • 26 jun
    Original: Multiple sclerosis and related disorders

    Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study

    Background: Spasticity and urinary disturbances can profoundly impact the daily lives of persons with multiple sclerosis (pwMS). Cannabis has been associated with improvement in sphincteric disturbances. To our knowledge, few studies have evaluated the effect of nabiximols oromucosal spray (Sativex®) on urinary disturbances by instrumental methods. Objectives: This longitudinal study was conducted to assess the effect of […]

    Læs mere
  • 26 jun
    Original: Clinical kidney journal

    Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study

    Background: Chronic pain is prevalent but difficult to treat in patients undergoing hemodialysis (HD). Effective and safe analgesics are limited in this patient population. Our aim in this feasibility study was to evaluate the safety of sublingual oil based medical cannabis for pain management in patients undergoing HD. Methods: In a prospective randomized, double-blind, cross-over design, patients […]

    Læs mere
  • 26 jun
    Original: Expert review of neurotherapeutics

    Clinical outcome data of chronic pain patients treated with cannabis-based oils and dried flower from the UK Medical Cannabis Registry

    Background: The following study evaluated the clinical outcomes of patients enrolled in the UK Medical Cannabis Registry, who were treated with inhaled dried flower (Adven® EMT2, Curaleaf International, Guernsey), and sublingual/oral medium-chain triglyceride-based oils (Adven, Curaleaf International, Guernsey) for chronic pain. Methods: In this cohort study, the primary outcomes were changes in validated patient reported outcome measures […]

    Læs mere
  • 26 jun
    Original: bioRxiv : the preprint server for biology

    Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: a pilot study

    Background: Individuals with schizophrenia are at elevated genetic risks for comorbid cannabis use, and often experience exacerbations of cognitive and psychotic symptoms when exposed to cannabis. These findings have led a number of investigators to examine cannabinoid CB1 receptor (CB1R) alterations in schizophrenia, though with conflicting results. We recently demonstrated the presence of CB1R in both […]

    Læs mere
  • 24 jun
    Original: Pharmaceutics

    Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns

    Multiple sclerosis (MS) is a complicated condition in which the immune system attacks myelinated axons in the central nervous system (CNS), destroying both myelin and axons to varying degrees. Several environmental, genetic, and epigenetic factors influence the risk of developing the disease and how well it responds to treatment. Cannabinoids have recently sparked renewed interest […]

    Læs mere
  • 24 jun
    Original: Current Pain and Headache Reports

    Evidence-Based Treatment of Pain in Chemotherapy-Induced Peripheral Neuropathy

    Purpose of review: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and often painful condition that occurs after administration of chemotherapeutic agents. The primary objective of this systematic review was to appraise the literature on conservative, pharmacological, and interventional treatment options for CIPN pain. Recent findings: There is level I evidence supporting modest to moderate improvement in CIPN […]

    Læs mere
  • 24 jun
    Original: J Clin Med

    Mediators of Placebo Response to Cannabinoid Treatment in Children with Autism Spectrum Disorder

    The placebo response has a substantial impact on treatment outcome. However, data regarding mediators of the placebo response in children with autism spectrum disorder (ASD) are sparse. This retrospective study investigated possible mediators of the placebo response among participants of a placebo-controlled trial of cannabinoid treatment for behavioral problems in children with ASD (CBA trial, […]

    Læs mere
  • 24 jun
    Original: Epilepsia

    Seizure-free days as a novel outcome in patients with Lennox-Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials

    Objective: In this post hoc analysis, we aimed to assess seizure-free days as a potential new outcome measure to use in randomized placebo-controlled trials (RCTs) of patients with Lennox-Gastaut syndrome (LGS). Methods: In two phase 3 RCTs (GWPCARE3, GWPCARE4), eligible patients were randomized to receive plant-derived highly purified cannabidiol (CBD; Epidiolex® in the USA; 100 mg/mL oral […]

    Læs mere
  • 24 jun
    Original: Epilepsia Open

    Cannabidiol in the acute phase of febrile infection-related epilepsy syndrome (FIRES)

    Febrile infection-related epilepsy syndrome (FIRES) is a prolonged refractory status epilepticus (SE) that develops among healthy individuals after a febrile infection. FIRES treatment is challenging due to its poor response to antiseizure medications (ASMs) and anesthetic drugs. The use of cannabidiol (CBD) as an adjunctive treatment has been suggested, albeit data about its role in […]

    Læs mere
  • 24 jun
    Original: Cannabis Cannabinoid Res .

    Chronic Effects of Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure in Patients with Hypertension (HYPER-H21-4): A Randomized, Placebo-Controlled, and Crossover Study

    Background: Recent data indicate that cannabidiol (CBD), a nonintoxicating constituent of cannabis, is involved in several aspects of cardiovascular regulation, including blood pressure (BP). However, the impact of chronic CBD administration on 24-h BP and vascular health has not been previously examined in patients with hypertension. The primary aim of this randomized, triple-blind, placebo-controlled, and crossover […]

    Læs mere
  • 24 jun
    Original: Cannabis Cannabinoid Res .

    Effectiveness and Safety of Cannabinoids as an Add-On Therapy in the Treatment of Resistant Spasticity in Multiple Sclerosis: A Systematic Review

    Background: Spasticity continues to be a very prevalent, highly invalidating, and difficult-to-manage symptom in patients with multiple sclerosis (MS). The aim of this systematic review is to evaluate the effectiveness of the use of cannabis and cannabinoids in these patients, evaluating its use as an additional therapy. Methods: We performed a systematic review of the literature searching […]

    Læs mere
  • 24 jun
    Original: Brain Sci .

    Influence of Cannabinoid Treatment on Trajectories of Patient-Related Outcomes in Chronic Pain: Pain Intensity, Emotional Distress, Tolerability and Physical Disability

    The treatment of chronic pain with cannabinoids is becoming more widespread and popular among patients. However, studies show that only a few patients experience any benefit from this treatment. It also remains unclear which domains are affected by cannabinoid treatment. Therefore, the present study is novel in that it explores the effects of cannabinoid treatment […]

    Læs mere
  • 22 jun
    Original: British journal of pain

    Medicinal cannabis for Australian patients with chronic refractory pain including arthritis

    Objectives: To examine the tolerability and effectiveness of medicinal cannabis prescribed to patients for chronic, refractory pain, with a subset analysis on arthritis. Methods: This was an interim analysis of the CA Clinics Observational Study investigating self-reported adverse events (AEs) and changes in health-related quality of life (HRQoL) outcomes over time after commencing medicinal cannabis. Patients were […]

    Læs mere
  • 22 jun
    Original: Neurobiology of learning and memory

    Cannabinoid modulation of corticolimbic activation during extinction learning and fear renewal in adults with posttraumatic stress disorder

    Failure to successfully extinguish fear is a hallmark of trauma-related disorders, like posttraumatic stress disorder (PTSD). PTSD is also characterized by dysfunctional corticolimbic activation and connectivity. The endocannabinoid system is a putative system to target for rescuing these behavioral and neural deficits. In healthy adults, acute, low-dose delta-9-tetrahydrocannabinol (THC) facilitates fear extinction and increases cortico-limbic […]

    Læs mere
  • 22 jun
    Original: Nature and science of sleep

    Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey

    Introduction: Sleep disorders are the third most common indication for the prescription of medical cannabis products in Australia, after pain and anxiety. While the use of cannabis for medical purposes is growing in Australia, underlying consumer behaviours and patterns of use, particularly around sleep disorders, are poorly understood. Methods: We conducted a subanalysis of the cross-sectional “Cannabis […]

    Læs mere
  • 22 jun
    Original: Cancers

    A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer

    Purpose: Cannabinoids (CBD) have anti-tumor activity against prostate cancer (PCa). Preclinical studies have demonstrated a significant decrease in prostate specific antigen (PSA) protein expression and reduced tumor growth in xenografts of LNCaP and DU-145 cells in athymic mice when treated with CBD. Over-the-counter CBD products may vary in activity without clear standardization, and Epidiolex is a […]

    Læs mere
  • 22 jun
    Original: World journal of clinical cases

    Medicinal cannabis products for the treatment of acute pain

    For thousands of years, medicinal cannabis has been used for pain treatment, but its use for pain management is still controversial. Meta-analysis of the literature has shown contrasting results on the addition of cannabinoids to opioids compared with placebo/other active agents to reduce pain. Clinical studies are mainly focused on medicinal cannabis use in chronic […]

    Læs mere
  • 18 maj
    Original: Journal of clinical nursing

    Symptom severity is a major determinant of cannabis-based products use among people with multiple sclerosis

    Aims and objectives: We aimed to identify correlates of cannabinoid-based products (CBP) use in patients with multiple sclerosis (MS) in France and Spain. Background: MS is responsible for a wide range of symptoms, including pain. Access to CBP differs according to local legislation. The French context is more restrictive than the Spanish one, and no data regarding […]

    Læs mere
  • 18 maj
    Original: BMC neurology

    Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity

    Background: Nabiximols (Sativex®) is a cannabinoid approved for multiple sclerosis (MS)-related spasticity. Its mechanism of action is partially understood, and efficacy is variable. Objective: To conduct an exploratory analysis of brain networks connectivity changes on resting state (RS) functional MRI (fMRI) of MS patients treated with nabiximols. Methods: We identified a group of MS patients treated with Sativex® […]

    Læs mere
  • 18 maj
    Original: The International journal of neuroscience

    A 3-year-old child with multi-drug resistant epilepsy responding to pharmacological and nonpharmacological treatments

    Introduction: Despite the development of new antiseizure drugs (ASDs), around one third of epilepsy patients become refractory to treatment or experience adverse events due to ASDs. Therefore, discovery of new ASDs and new therapy options are crucial to improve the quality of life. Herein, we report a 3-year-old child with multi-drug resistant epilepsy caused by perinatal […]

    Læs mere
  • 18 maj
    Original: Journal of clinical oncology

    Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)

    Purpose: To determine whether cannabidiol (CBD) oil can improve symptom distress in patients with advanced cancer receiving palliative care. Methods: Participants were adults with advanced cancer and symptom distress (Edmonton Symptom Assessment Scale [ESAS] total score of ≥ 10/90) who received titrated CBD oil 100 mg/mL, 0.5 mL once daily to 2 mL three times a day, […]

    Læs mere
  • 18 maj
    Original: Frontiers in psychiatry

    Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state

    Adolescent individuals often present with subtle, sub-threshold psychiatric syndromes that fluctuate or persist for years. These symptoms have been classified as Clinically High-Risk mental states (CHR), negatively affecting these individuals’ psychosocial development and integration by reducing performance and affecting interpersonal relations. The pathophysiological underpinnings have not been studied in detail, contributing to the current lack […]

    Læs mere
  • 17 maj
    Original: Cannabis and Cannabinoid Research

    Cannabidiol Add-On in Glycosylphosphatidylinositol-Related Drug-Resistant Epilepsy

    Background: Glycosylphosphatidylinositol-anchored protein deficiencies (GPI-ADs) are commonly associated with drug-resistant epilepsy (DRE). Cannabidiol (CBD) is approved for the adjunctive treatment of seizures in Dravet/Lennox-Gastaut Syndromes and Tuberous Sclerosis Complex. We report on the efficacy and safety of CBD for the treatment of DRE in patients with genetically proven GPI-AD. Patients and Methods: Patients received add-on treatment with purified […]

    Læs mere
  • 17 maj
    Original: International Journal of Environmental Research and Public Health

    A Survey of Cannabis Use among Patients with Inflammatory Bowel Disease (IBD)

    Inflammatory bowel diseases (IBDs) are chronic conditions of unknown cause or cure. Treatment seeks to reduce symptoms and induce and maintain remission. Many patients have turned to alternatives, such as cannabis, to alleviate living with IBD. This study reports the demographics, prevalence, and perception on cannabis use of patients attending an IBD clinic. Patients agreed […]

    Læs mere
  • 17 maj
    Original: Viruses

    The Combined Effects of Cannabis, Methamphetamine, and HIV on Neurocognition

    Objective: Methamphetamine and cannabis are two widely used substances among people living with HIV (PLWH). Whereas methamphetamine use has been found to worsen HIV-associated neurocognitive impairment, the effects of combined cannabis and methamphetamine use disorder on neurocognition in PLWH are not understood. In the present study, we aimed to determine the influence of these substance use […]

    Læs mere
  • 17 maj
    Original: Supportive Care in Cancer

    MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse events

    Background: Approximately 18% of patients with cancer use cannabis at one time as palliation or treatment for their cancer. We performed a systematic review of randomized cannabis cancer trials to establish a guideline for its use in pain and to summarize the risk of harm and adverse events when used for any indication in cancer patients. […]

    Læs mere
  • 17 maj
    Original: Current Pain and Headache Reports

    Medical Cannabis for Chronic Nonmalignant Pain Management

    Purpose of review: Cannabis has been used since ancient times for medical and recreational research. This review article will document the validity of how medical cannabis can be utilized for chronic nonmalignant pain management. Recent findings: Current cannabis research has shown that medical cannabis is indicated for symptom management for many conditions not limited to cancer, chronic […]

    Læs mere
  • 17 maj
    Original: Drug Metabolism and disposition: The biological fate of chemicals

    A Physiologically-Based Pharmacokinetic Model for Cannabidiol in Healthy Adults, Hepatically-Impaired Adults, and Children

    Cannabidiol (CBD) is available as a prescription oral drug that is indicated for the treatment of some types of epilepsy in children and adults. CBD is also available over-the-counter and is used to self-treat a variety of other ailments, including pain, anxiety, and insomnia. Accordingly, CBD may be consumed with other medications, resulting in possible […]

    Læs mere
  • 9 maj
    Original: Clin Neuropharmacol

    Medical Cannabis in the Treatment of Parkinson’s Disease

    Objectives: Medical cannabis (MC) has recently garnered interest as a potential treatment for neurologic diseases, including Parkinson’s disease (PD). A retrospective chart review was conducted to explore the impact of MC on the symptomatic treatment of patients with PD. Methods: Patients with PD treated with MC in the normal course of clinical practice were included (n = […]

    Læs mere
  • 9 maj
    Original: Psychiatry Res

    CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders – Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study

    Preliminary data suggest that cannabis-based medicines might be a promising new treatment for patients with Tourette syndrome (TS)/chronic tic disorders (CTD) resulting in an improvement of tics, comorbidities, and quality of life. This randomized, multicenter, placebo-controlled, phase IIIb study aimed to examine efficacy and safety of the cannabis extract nabiximols in adults with TS/CTD (n […]

    Læs mere
  • 9 maj
    Original: Cannabis Cannabinoid Res

    Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock?

    Obesity and nonalcoholic fatty liver disease (NAFLD) constitute global and growing epidemics that result in therapeutic dead ends. There is an urgent need for new and accessible treatments to improve and widen both preventive and curative approaches against NAFLD. The endocannabinoid system (ECS) is recognized as a complex signaling apparatus closely related to metabolic disorders […]

    Læs mere
  • 9 maj
    Original: J Clin Med

    A Retrospective Medical Record Review of Adults with Non-Cancer Diagnoses Prescribed Medicinal Cannabis

    Research describing patients using medicinal cannabis and its effectiveness is lacking. We aimed to describe adults with non-cancer diagnoses who are prescribed medicinal cannabis via a retrospective medical record review and assess its effectiveness and safety. From 157 Australian records, most were female (63.7%; mean age 63.0 years). Most patients had neurological (58.0%) or musculoskeletal […]

    Læs mere
  • 9 maj
    Original: Biomedicines

    The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study

    Mastocytosis patients often experience a number of symptoms, including mastocytosis-associated pain that is difficult to manage due to resistance to usual antalgic treatments and/or the patient’s poor tolerance. Mastocytosis patients display significantly higher levels of indoleamine-2,3-dioxygenase-1 (IDO1) activity, leading to hyperactivation of the N-methyl-D-aspartate receptor. As cannabidiol (CBD) is known to inhibit IDO1’s enzymatic activity, […]

    Læs mere
  • 9 maj
    Original: Int J Environ Res Public Health

    Evidence from Human Studies for Utilising Cannabinoids for the Treatment of Substance-Use Disorders: A Scoping Review with a Systematic Approach

    Substance-use disorders are pervasive, comorbid with a plethora of disease and possess limited treatment options. Medicinal cannabinoids have been proposed as a novel potential treatment based on preclinical/animal trials. The objective of this study was to examine the efficacy and safety of potential therapeutics targeting the endocannabinoid system in the treatment of substance-use disorders. We […]

    Læs mere
  • 9 maj
    Original: BMC Complementary Medicine and Therapies

    Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial

    Background: Although topical steroids constitute the first-line therapy for recurrent aphthous ulcers (RAUs), their long-term use often leads to candidiasis. Although cannabidiol (CBD) can be an alternative for pharmacologically managing RAUs due to its analgesic and anti-inflammatory in vivo effects, there is a lack of clinical and safety trials concerning its use. The aim of this […]

    Læs mere
  • 9 maj
    Original: Cannabis Cannabinoid Res

    The Cannabis-Dependent Relationship Between Methadone Treatment Dose and Illicit Opioid Use in a Community-Based Cohort of People Who Use Drugs

    Background: Methadone maintenance treatment (MMT) is an effective treatment for opioid use disorder. However, subtherapeutic dosing may lead to continued opioid use by failing to suppress opioid withdrawal and craving. Preclinical and pilot experimental research suggests that cannabinoids may reduce opioid withdrawal and craving. We sought to test whether the association between low methadone dose and […]

    Læs mere
  • 9 maj
    Original: Front Pharmacol

    Pharmacovigilance on cannabidiol as an antiepileptic agent

    Introduction: Cannabidiol (CBD) is an active chemical contained in the plant Cannabis sativa. It is a resorcinol-based compound that crosses the blood-brain barrier without causing euphoric effects. CBD has a plethora of pharmacological effects of therapeutic interest. CBD has been authorized in the European Union as an anticonvulsant against serious infantile epileptic syndromes, but its safety profile […]

    Læs mere
  • 9 maj
    Original: J Clin Med Res .

    Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation

    Background: Though viewed as a potentially safer palliative alternative to opioids, studies of cannabis use for inflammatory bowel disease (IBD) are limited. The impact of opioids on hospital readmissions for IBD has been extensively examined, but cannabis has not been similarly studied. Our goal was to examine the relationship between cannabis use and the risk of […]

    Læs mere
  • 9 maj
    Original: Expert Rev Neurother

    Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: A cohort study

    Introduction: There is growing evidence on the efficacy of cannabis-based medicinal products (CBMPs) for chronic pain (CP). Due to the interaction between CP and anxiety, and the potential impact of CBMPs on both anxiety and CP, this article aimed to compare the outcomes of CP patients with and without co-morbid anxiety following CBMP treatment. Methods: Participants were […]

    Læs mere
  • 9 maj
    Original: Clinical Neurology and Neurosurgery

    Second-line cannabis therapy in patients with epilepsy

    Objective: Marijuana-based therapies (MBTs) have been shown to reduce seizure frequency in patients with severe and drug-resistant epilepsy (DRE). Pharmaceutical-grade CBD (EpidiolexⓇ) was approved by the FDA in 2018 for the treatments of Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) and subsequently in 2020 for tuberous sclerosis complex (TSC). It is unclear what the utility would […]

    Læs mere
  • 16 apr
    Original: Iran J Pharm Res

    A Phase I Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety Profile of a Sublingually Administered Cannabidiol /Delta 9-tetrahydrocannabidiol (10: 1) Regimen in Diabetes Type 2 Patients

    The current study aimed to evaluate the safety profile and efficacy of a cannabis-based sublingual spray, CBDEX10® (containing 100 µg cannabidiol and 10 µg Δ9-tetrahydrocannabinol per puff; CBD/Δ9-THC 10:1), in improving lipid profile and glycemic state of the diabetic patients. Fifty diabetic patients were randomly allocated to the treatment (n = 25; receiving two puffs of […]

    Læs mere
  • 4 apr
    Original: JAMA Network

    Changes in Prescribed Opioid Dosages Among Patients Receiving Medical Cannabis for Chronic Pain, New York State, 2017-2019

    Importance: Patients with chronic pain often receive long-term opioid therapy (LOT), which places them at risk of opioid use disorder and overdose. This presents the need for alternative or companion treatments; however, few studies on the association of medical cannabis (MC) with reducing opioid dosages exist. Objective: To assess changes in opioid dosages among patients receiving MC […]

    Læs mere
  • 4 apr
    Original: Der Schmerz

    Benefits and harms of cannabis-based medicines from the viewpoint of patients with chronic pain and their physicians : A cohort study in three pain centers of the German federal state Saarland

    Background: There are no studies available that have simultaneously assessed the benefits and harms of cannabis-based medicines from the viewpoint of patients and their physicians. Methods: All chronic pain patients at three pain centres in the German federal state of Saarland who had received at least one prescription of cannabis-based medicines (CbMs) in the past from the […]

    Læs mere
  • 4 apr
    Original: Front Psychiatry

    Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions

    The majority of states have fully legalized the use of medical cannabis (MC), and nearly all other states allow limited access to cannabidiol (CBD), a non-intoxicating constituent of cannabis often touted for a range of therapeutic indications. Further, the Agricultural Improvement Act of 2018 legalized hemp-derived products in all 50 states; typically high in CBD, […]

    Læs mere
  • 4 apr
    Original: J Hand Surg Glob Online

    Hand Surgery Patient Perspectives on Medical Cannabis: A Survey of Over 600 Patients

    Purpose: Medical cannabis (MC) has been proposed as a potential addition to multimodal pain management regimens in orthopedics. This study evaluates hand and upper-extremity patient perspectives of MC as a treatment for common orthopedic and musculoskeletal pain conditions. This study also aims to identify the proportion of patients already using MC, perceived barriers to MC use, […]

    Læs mere
  • 4 apr
    Original: Biomedicines

    A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania

    Background: Cannabis use is increasing among adults to treat a variety of health conditions. Given the potential for interactions and adverse events, it is important to assess the use of medical cannabis along with other concomitant medications when assessing for polypharmacy. Methods: The objective of this observational, longitudinal study was to examine medical cannabis (MC) use along […]

    Læs mere
  • 4 apr
    Original: Clin Ter

    Oral thc: cbd cannabis extract in main symptoms of Alzheimer disease: agitation and weight loss

    Objectives: Ten million new cases of dementia are recorded annually worldwide, with agitation and idiopathic weight loss being the most common symptoms. Several pharmacological therapies have emerged in recent years, but the clinical use of cannabis extracts in older patients with AD is constantly growing. This retrospective, analytical, observational, spontaneous trial aimed to enhance the clinical […]

    Læs mere
  • 4 apr
    Original: PLoS One

    Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation

    This study sought to identify differences in cannabis use and perceptions about cannabis in mitigating seizure-related symptoms in patients with epilepsy, and to evaluate differences in these patterns between drug-resistant versus pharmacoresponsive epilepsy. A collection of self-report surveys completed by patients with epilepsy (n = 76) were used to retrospectively compare differences in those with […]

    Læs mere
  • 4 apr
    Original: Front Psychiatry

    Mental disorders are no predictors to determine the duration of cannabis-based treatment for chronic pain

    Background: Chronic pain (CP), a complex biopsychosocial disorder with a global prevalence of up to 33%, can be treated by following multidisciplinary approaches that may include cannabis-based medicine (CBM). However, because CBM continues to be a new treatment, questions remain regarding the ideal duration for CBM and its psychosocial determinants, including mental comorbidities. Methods: In a retrospective […]

    Læs mere
  • 27 mar
    Original: Brain & development

    Myoclonic super-refractory status epilepticus with favourable evolution in a teenager with FIRES: Is the association of vagus nerve stimulation and cannabidiol effective?

    Background: Febrile infection-related epilepsy syndrome (FIRES) is a rare and catastrophic clinical syndrome occurring in previously healthy patients. Aetiology is still unknown and outcome usually poor. We describe a case of myoclonic prolonged super refractory status epilepticus (P-SRSE) in FIRES in a patient admitted to the paediatric intensive care unit of Padova, Italy. Case report: A previously […]

    Læs mere
  • 24 mar
    Original: BMC Family Practice

    Physicians’ experiences, attitudes, and beliefs towards medical cannabis: a systematic literature review

    Background: An increasing number of countries legalise the use of medical cannabis or allow it for a narrow range of medical conditions. Physicians, and often the patients’ general practitioner, play a major role in implementing this policy. Many of them, however, perceive a lack of evidence-based knowledge and are not confident with providing patients with […]

    Læs mere